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ABSTRACT 
Injectable bone grafts are space-filling materials that integrate with native bone 
to repair large defects from congenital deformities, trauma, and tumor resection. 
However, current injectable bone grafts limit healing due to lack of biodegradability, 
high temperatures during hardening, reduced porosity, and brittle compressive 
properties.  
In this work, polymerized high internal phase emulsions (polyHIPEs) were 
developed as high porosity scaffolds for injectable bone grafting applications. Methods 
to modulate polyHIPE pore architecture, compressive properties, and degradation rates 
were established. Injectable polyHIPEs with pore sizes ranging from 1- 200 µm, 
compressive properties comparable to human cancellous bone, and degradation profiles 
spanning days to months were fabricated by altering compositional parameters (i.e. 
organic phase composition including macromers and surfactant, addition of an 
electrolyte in aqueous phase, and the phase in which initiator is soluble) and processing 
parameters (i.e. mixing speed, and cure and storage conditions). Cytocompatibility of all 
HIPE components was first verified and human mesenchymal stem cell (hMSC) 
adhesion and morphology was then assessed on polyHIPE sections. In order to confer an 
osteoinductive character to the bone grafts, calcium phosphate nanoparticles and 
demineralized bone matrix were incorporated into the polyHIPEs. PolyHIPE pore size 
and compressive properties were negligibly altered with the incorporation of particles. 
Alkaline phosphatase activity, a marker of osteoblast differentiation, was elevated from 
hMSCs on polyHIPE sections with osteoinductive particles. Finally, hMSC viability post 
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encapsulation in the polyHIPE was investigated to demonstrate the potential use as a cell 
carrier and viable cells were observed at 3 hours post encapsulation.  
Overall, these studies highlight the potential of injectable polyHIPEs as improved 
bone grafts that can deliver and retain autologous hMSCs at the defect site while also 
inducing osteogenic differentiation for enhanced bone regeneration. Elucidation of key 
structure-property relationships in emulsion templated scaffolds can be used in future 
studies to further modulate cell-material interactions. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
1.1 Clinical Need: Repair of Non-Union Bone Defects 
Musculoskeletal diseases and injuries result in over $250 billion spent in treatment 
and repair annually in the United States. Due to the range of conditions, the American 
Academy of Orthopedic Surgeons has characterized musculoskeletal diseases as the 
number one reason patients visit a doctor.1 Specifically, bone fractures comprise a 
majority of these disorders; however, there is a need for improved healing as 5-10% of 
the roughly 6.2 million bone fractures reported in the United States are associated with 
impaired healing.2 These defects result from traumatic injury, congenital deformities, 
and tumor resection. In general, bone has the ability to remodel and heal without 
scarring in smaller defects. However, at a critical size, defects are no longer able to heal 
naturally requiring reconstructive surgery to repair the defect. Key’s Hypothesis states in 
skeletally mature dogs that a segmental long bone defect that exceeds 1.5X the 
diaphyseal diameter surpasses the regenerative capacity and is termed a critical size 
defect.3, 4 Therefore, critical size defects are utilized as experimental models to test the 
efficacy of bone graft materials.  
Bone functions to provide support for the body, structure for muscle contraction, acts 
as a reservoir for minerals, a site of hematopoiesis (bone marrow), and protects internal 
organs.5 Bone is the primary calcium reservoir for the body and is responsible for the 
timely exchange of ions with the extracellular environment.6 Native bone is comprised 
of two distinct tissue architectures: cortical and trabecular (cancellous) bone. Cortical 
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bone is relatively non-porous (~10% porosity) and comprised of extracellular matrix 
components (mainly calcium phosphate) that dictate the high compressive strength and 
modulus of bone (E=10-20 GPa).7 Cortical bone makes up ~80% of the skeleton and 
constitutes long bones, short bones, and flat bones. Trabecular, or spongy, bone 
constitutes ~20% of the skeleton and is porous (50-90%) resulting in compressive 
modulus values much lower than cortical bone (E=20-500 MPa)7. Trabecular bone is 
typically found in the metaphysis of long bones and has a honeycomb-like pore 
structure. The periosteum is a thin membrane surrounding the outer surface of bones 
containing progenitor cells. The reparative nature of bone involves a dynamic 
relationship between osteoblasts, which produce and lay down supportive extracellular 
matrix, and osteoclasts, which resorb old or damaged tissue to make space for new 
matrix and healthy tissue. Osteocytes are mature osteoblasts that control the extracellular 
calcium and phosphorus concentrations and direct osteogenesis and resorption 
depending on the environment conditions via cell-cell interactions.8 When the 
equilibrium of the bone cells is off, bone loss occurs which greatly affects the quality of 
life for the patient. Bone extracellular matrix, which provides much of the stellar 
qualities that bone encompasses, is comprised of hydroxyapatite, a mineral component, 
and an organic component. Hydroxyapatite composes 65-70% of the bone matrix and the 
organic constituents (glycoproteins, proteoglycans, and sialoproteins) make up the 
remainder.9 Stimulating the natural repair process of bone in critical size defects is 
crucial in reestablishing support and quality of life to patients plagued with critical size 
bone fractures.  
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1.1.1 Natural Bone Healing  
Unlike most tissues in which healing includes the formation of scar tissue, bone 
heals efficiently resulting in healthy new bone produced.6 Bone tissue is in a constant 
state of rejuvenation – end-stage differentiated cells such as osteoblasts are replaced by 
newly differentiated osteoblasts geared for forming new bone. These young osteoblasts 
arise from multipotent progenitor cells known as mesenchymal stem cells (MSCs) which 
circulate in the bone marrow.8, 10 Thus, these MSCs have a vital role in serving as the 
depot center for bone healing and repair. 
1.1.1.1 Inflammatory Stage  
During this first stage of bone healing, a hematoma forms and inflammatory cells 
and fibroblasts move into the fracture site resulting in granulation tissue formation, 
ingrowth of vascular tissue, and migration of mesenchymal stem cells.8, 11 Platelets 
release transforming growth factor beta (TGF-β) and platelet-derived growth factor 
(PDGF) which induce angiogenesis as well as MSC migration and proliferation. BMPs 
are released from underlying bone matrix as well as secreted by recruited MSCs.12 
1.1.1.2 Repair Stage  
During the period of fibrocartilaginous callus formation, fibroblasts lay down a 
collagen matrix as vascular ingrowth occurs and chondroblasts produce fibrocartilage 
which is stronger to bridge the gap of the defect. Vascular ingrowth is controlled by 
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 
1 and 2.13, 14 Osteoblasts secrete osteoid, the unmineralized matrix composed of Type 1 
collagen and proteoglycans, which is mineralized over time into a soft callus during the 
 4 
 
bony callus formation period. The ossification of the soft callus to bridge the broken 
bones happens in 4 to 6 weeks if the bone is properly immobilized. New bone formation 
occurs via intramembranous or endochondral ossification which is dictated by the 
mechanical nature of the break – mechanically stable fractures heal by direct bone 
matrix formation void of cartilage whereas unstable fractures heal via the endochondral 
process in which cartilage is generated and remodeled as bone tissue.15, 16 Mineralization 
refers to the general process of depositing mineral salts via calcification or ossification. 
Calcification is the deposition of calcium in tissues and occurs when the solubility of 
calcium in the interstitial fluid of specific tissues is exceeded. Ossification is the specific 
and organized deposition of calcium salts onto the collagen matrix that constitutes the 
osteoid and is specific to bone mineralization.6 
1.1.1.3 Late Remodeling Stage  
In this final stage of bone healing, remodeling occurs to ensure the neotissue is of 
adequate shape, structure, and strength. This process is dictated by mechanical loading 
as stated in Wolff’s Law and can take months to years.17 Adequate strength is commonly 
achieved in 3 – 6 months.  
1.1.1.4 Role of Mesenchymal Stem Cells and the Trophic Effect 
Marrow-derived mesenchymal stem cells are undifferentiated cells capable of 
differentiating into cells of mesenchymal tissue including bone, cartilage, connective 
tissue (tendons and ligaments), muscle, and fat.18, 19 MSCs located within the periosteum 
and the marrow serve as the generals of the musculoskeletal healing army and are 
constantly surveying for damage and ready to signal for repair. In 2006, Arnold Caplan 
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and colleagues proposed with supporting evidence that MSCs were not necessarily 
differentiating into specific cells but rather releasing cytokines and growth factors to 
achieve a therapeutic effect, termed a trophic effect.20 Multiple studies investigating 
treatment of cardiac ischemia, osteoarthritis, and stroke illustrated tissue repair after the 
delivery of MSCs to the defect site. However, in each of these studies, the MSCs did not 
differentiate into the specific cells required for new tissue formation. Instead, they acted 
as leaders recruiting and directing nearby cells to repair the damaged tissue via 
biochemical signals. Caplan determined five processes in which MSCs exhibit this 
trophic effect: they reduce apoptosis, limit fibrosis and scar formation, promote 
angiogenesis and blood vessel formation to enhance healing, stimulate the mitosis of 
tissue-specific progenitor cells, and release immunomodulatory chemicals that block T-
cell surveillance suggesting the successful use of allogenic and xenogenic cells.21 Recent 
work exemplifies these trophic properties in MSCs aiding in cardiac repair and the 
viable delivery and function of transplanted islets, chondrocytes, and Schwann cells to 
name a few of the cells being tested.22-27 Researchers have shown MSCs may play a role 
in tumor suppression further illustrating the vitality of MSC delivery in tissue 
engineering and regenerative medicine.28 The continuous increase in knowledge of bone 
biology, physiology, and fracture healing processes is advantageous in designing 
treatment options that best capitalize on the necessary tools to aid in long-term healing 
and reduce scarring.  
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1.2 Current Treatment Options 
Annually, over 1 million patients with bone defects require grafts to provide 
complete union.29 Even though bone grafting procedures have been performed for the 
past two centuries to provide a template for new growth, healing is still limited in large 
defects. For adequate healing, the overall goal of bone grafts is to capitalize on the 
body’s natural ability to lay down new bone matrix and calcify under the mechanical 
stresses of the body. Therefore, the actual graft must provide initial mechanical integrity, 
promote osteogenesis and calcified matrix production, and degrade (including resorption 
and clearance by the body) once new tissue is formed.6 Bone grafts are classified by the 
extent to which they promote osteogenesis. Osteoconductive grafts guide bone healing in 
the presence of all other necessary cues.30 These materials promote infiltration of 
neovasculature and ingrowth of precursor cells. Osteoinductive materials can promote 
the osteogenic differentiation of stem cells into mature osteoblasts which can lay down 
new extracellular matrix. Biochemical promoters of osteogenesis such as bone 
morphogenetic proteins are examples of osteoinductive components.   
1.2.1 Autografts  
Autologous grafts are the gold standard for repair due to their osseointegration 
(ability of material to integrate with host bone), osteoinductivity, (ability to provide cues 
for the differentiation of stem cells to osteoblasts) and the lack of immune rejection. 
Commonly, bone harvested from the patient’s iliac crest of the hip, rib, tibia, mandible, 
or skull is used to treat segmental defects or shaved and packed into smaller injury 
sites.31 Success rates are generally high, between 70-100% in vertebral fusions which is 
 7 
 
one of the most common uses for autografts.32 Unfortunately, retrieval of tissue from the 
patient is limited due to anatomical availability and leads to donor site pain and 
morbidity.32-34  
1.2.2 Allografts  
Allograft bone is harvested from the same species and is typically obtained from 
cadaveric tissue in bone banks or commercial vendors.35 This type of treatment is often 
used because of the increased availability relative to autografts. For the repair of 
segmental defects, cadaveric bone is decellularized to reduce immune rejection and the 
remaining matrix is used for repair. Depending on the defect geometry, it may be 
difficult to adequately fit allograft material into the defect site. Alternatively, cadaveric 
tissue can be demineralized and used as a paste to pack into the stabilized defect. 
However, the demineralization process reduces the loading ability of the graft. Allografts 
are typically osteoconductive due to the decellularization and demineralization 
procedures. Allograft particles can be added to a polymeric matrix for delivery and 
enhanced mechanical properties. Dumas et al. fabricated injectable 
polyurethane/allograft composites with a range of properties, degradation rates, and 
compressive properties on the low end of cancellous bone illustrating the ability to 
combine allograft particles with synthetic materials to increase mechanical integrity.36 In 
general, autografts and allografts suffer from variability (quality of tissue from patient to 
patient) and limited availability necessitating the need for a reliable and viable bone graft 
option. 
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1.2.3 Poly(methyl methacrylate) Bone Cement  
Poly(methyl methacrylate) (PMMA) bone cement is the most commonly utilized 
synthetic formulation in bone repair. In segmental defect repair, PMMA cement is used 
in fracture fixation to secure the metal implants into the native bone. In smaller 
applications such as vertebroplasties, cement is used to fill the defect site and withstand 
part of the load. Since the 1960s, surgeons have used this injectable cement formulation 
because of its viscosity, rheological, and cure properties.37 Injectable PMMA cement is 
sold as two components: PMMA polymer powder with a radical initiator, benzoyl 
peroxide, and methyl methacrylate monomer. Upon mixing of the two phases, a 
paste/putty results and is easily applied to the defect. However, the exothermic 
temperature reached during PMMA polymerization exceeds 100ºC and has caused tissue 
necrosis and required revision surgery.38, 39 PMMA bone cement is also not porous 
limiting cell migration, nutrient and waste transport, and tissue ingrowth. Furthermore, 
PMMA is not biodegradable resulting in residual material in the body which could 
impede bone healing. 
1.2.4 Injectable Materials  
Bone cements that flow at room temperature and harden once injected into the 
body are commonly utilized to heal non-union defects because they can fill irregularly 
shaped defects and harden without an additional stimulus. The availability, tunability, 
and mechanical properties of synthetic materials address inherent issues with autografts 
and allografts. 
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1.2.4.1 Calcium Phosphate Cements  
Calcium phosphate cements have been used for bone grafting procedures since 
the 1980s due to their excellent biocompatibility and osteoconductivity.1 Various 
formulations and fabrication techniques have been investigated resulting in  
 
 Table 1.1. Selected calcium phosphate cement formulations and properties
40 
Origin Material Pore Size (µm) Compressive Strength (MPa) 
Bovine HA 100-1500 4.2-5.6 
Bovine 60% HA/40% H2O 390-1360 1.0-20.0 
Coral HA 28-770 - 
Synthetic β-TCP 100-400 - 
Synthetic β-TCP 1-1000 - 
Synthetic 80% TCP/20% HA 300-500 - 
Synthetic TTCP/DCP 2-50 6.3-34 
Synthetic 
62.5% α-TCP 
26.8% DCPA 
8.9% CaCO3 
1.8% HA 
<1 35-55 
Synthetic 60% HA/40% β-TCP - - 
Synthetic 
73% β-TCP 
21% MCP-H2O 
5% MHPT 
- - 
Synthetic TTCP/DCP/TSC - 14-24 
Synthetic 
α-TCP/CaCO3/ 
MCP-H2O 
- 23-55 
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commercialization of many products illustrated in Table 1.1. In general, these pastes 
consist of two or more calcium phosphate compositions mixed with an aqueous solution 
with hardening occurring after mixing due to dissolution and precipitation.41 Altering 
processing parameters, particle size, cement compositions, and additives are ways to 
tune cement set times. In general, CaP cements exhibit low fracture toughness and 
mechanical reliability as determined by the Weibull modulus which determines the 
probability of failure of brittle materials.42 
1.3 Tissue Engineered Bone Grafts   
Tissue engineering strategies combine the osseointegration and osteoinductivity 
of autografts with the availability and tunability of synthetic grafts to avoid 
complications.43, 44 Tissue engineering strategies focus on harnessing the body’s natural 
healing potential by providing 3-dimensional (3D) scaffolds embedded with instructive 
cues and human cells which promote new tissue formation. Tissue engineering 
constructs promote bone regeneration by instructing endogenous or seeded cells with 
appropriate bioactive cues to aid in cell differentiation and tissue growth.45 Utilizing 
tissue engineering to regenerate bone requires the development of an osteoconductive 
matrix that promotes osteogenesis of encapsulated or endogenous osteoprogenitor cells 
via an osteoinductive factor. 
1.3.1 Requirements for 3D Scaffolds 
1.3.1.1 Pore Size  
The collection of research conducted on the effect of pore size on osteogenesis 
and fully vascularized new bone indicates pore sizes greater than 300 µm is necessary 
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for bone ingrowth and capillary formation.46 In polyHIPE literature, Akay et al.  
illustrated enhanced bone nodule formation from osteoblasts seeded on scaffolds with 
100 µm pore sizes compared to smaller pores.47 Work from the Mikos lab illustrated 
enhanced alkaline phosphatase activity, an early indicator of osteogenesis, of osteoblasts 
seeded on porous PLGA scaffolds with 500 – 700 µm pores.48 
 1.3.1.2 Interconnected Pore Architecture  
 It is well regarded in tissue engineering the importance of the pore size and 
interconnects between pores for ingrowth and proliferation of cells and the transport of 
nutrients and waste to maintain cell viability. The importance of interconnectivity on 
maintenance of cell viability in constructs with relatively small pore size has been 
recorded. Specifically, human embryonic stem cell-derived cardiomyocytes seeded on 
bimodal porogen-leached scaffolds with interconnected pores 30-40 µm remained 
viability for at least 2 weeks at a depth of 300 µm.49 Additional work by Marcacci et al. 
demonstrated the critical importance of interconnected porosity on vascularization and 
full healing in a long bone segmental defect clinical trial.50    
1.3.1.3 Adequate Mechanical Strength  
For bone tissue engineering, the biomaterial must be able to withstand loading 
imparted while the defect is immobilized. Additionally, Wolff’s law highlights the 
importance of compressive stress on the biomechanics of osteogenesis and resorption.17 
The maximum compressive forces loading on human bones has been estimated at 20-51 
MPa.51 Although bulk polymers could be designed to withstand these stresses, it is 
difficult to design highly porous scaffolds able to support this magnitude of load. 
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Fortunately, it is accepted that materials with compressive properties similar to 
cancellous bone (modulus = 30-100 MPa and strength = 2-10 MPa) are adequate to 
promote full bone healing.46, 52, 53 
1.3.1.4 Degradation Rate Matching In Vivo Healing  
Tissue engineered materials are designed to provide the necessary physiological 
matrix and cues to stimulate growth. To this end, 3D scaffolds are designed and tuned to 
degrade once new, stable tissue has been formed. Work conducted by Dr. Guelcher 
sheds new light on the necessary scaffold mechanical properties for healing in a rabbit 
femoral defect illustrating enhanced healing at later time points when 
polyurethane/allograft scaffold degradation rates closely matched those of new bone 
formation.54 Designing and fabricating scaffolds with tunable degradation rates is 
advantageous as the healing environment (enzymes, pH, etc.) differs from patient to 
patient and for various applications. 
 1.3.1.5 Injectability  
 A relatively new push has been on the design of materials that harden and mold 
to the desired shape in vivo to reduce the time and cost required to fabricate scaffolds via 
a 3D reconstruction of a defect based on a computer-aided design model. Furthermore, 
these injectable materials can completely space-fill any irregularly shaped defect without 
a gap and are less invasive methods to heal tissue.35 This is important to promote native 
cell infiltration and migration and eliminate any micromotion from occurring which 
could result in inflammation and scar tissue formation. For the delivery of cells and 
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growth factors, aqueous based systems such as hydrogels are advantageous in promoting 
viability and maintaining bioactivity of encapsulated biologics. 
1.3.2 3D Scaffold Fabrication Techniques  
Material scientists have developed a multitude of 3D porous scaffold fabrication 
techniques for use in various applications. The most common techniques used to 
generate highly porous scaffolds for tissue engineering applications include 
electrospinning, gas foaming, porogen leaching, thermally induced phase separations, 
and hydrogels. Specifically, these techniques paired with the macromer/polymer 
chemistries used result in constructs with tunable properties for use in soft and hard 
tissue applications. A particular difficult design problem is generating highly porous 
scaffolds that retain good mechanical properties. 
1.3.2.1 Electrospinning  
Electrospinning is a method utilized to produce fibrous meshes with tunable pore 
sizes, large surface area to volume ratios, and fibers of nano- to micron-sized 
diameters.55, 56 Altering system parameters (accelerating voltage, distance to the 
collector, spinning time, collector geometry, and environmental humidity) and polymer 
solution parameters (viscosity, hydrophobicity, and dielectric constant of the solvent) 
result in widely tunable fiber diameters and alignments.57 However, the resulting meshes 
are typically 2D limiting this technique for use in space-filling an irregularly shaped 
defect in the surgical suite. 
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1.3.2.2 Gas Foaming  
Generating gas, typically CO2, utilizing chemical or physical processes is 
utilized to produce pores.58, 59 Overall porosity of 94% with pore sizes from 100-500 µm 
can be achieved in this manner. This process is advantageous because it can be 
performed without the use of toxic solvents; however, a non-porous skin layer typically 
forms on the surface of the scaffold which must be removed prior to implantation.58 
Furthermore, this fabrication technique generally utilizes high temperatures and 
pressures limiting their formation in situ. 
1.3.2.3 Porogen Leaching  
In this technique, porogens, traditionally salts, are dispersed in a polymer 
solution and leached out after the network is formed to create pores.60, 61 Interconnected 
pores are formed by the fusing together of the porogens.62 Biodegradability and 
injectability are achieved depending on the polymer and porogen utilized.49, 63, 64 Pore 
sizes and shapes are dictated by the size and shape of the porogen. Thus, often the pores 
are irregularly shaped causing stress concentrators and decreasing the overall mechanical 
properties and the ability to dictate these properties.61, 65-68  
1.3.2.4 Thermally Induced Phase Separation  
Porous scaffolds are fabricated by inducing phase separation in a polymer 
solution to create polymer-rich and polymer-poor regions. The solvent is then removed 
via sublimation, similar to the removal of water in freeze-drying processes, resulting in a 
porous scaffold. The polymers, temperatures, and procedures used to sublimate the 
solvent modulate the tunable pore architecture ranging from long, aligned to spherical 
 15 
 
pores.69, 70 However, this procedure requires solvents and cold temperatures reducing the 
ability to use this as an injectable system for the delivery of cells.  
1.3.2.5 Shape Memory Foams  
The term shape memory polymers (SMPs) have been utilized to describe systems 
that capitalize on inherent polymer thermal properties to tune network properties. These 
systems have garnered interest for medical applications due to their ability to be 
designed in an original shape, molded into a temporary shape for delivery through a 
catheter or small vehicle, and expanded to the original shape once an energy stimulus 
such as heat or UV light are applied.71 SMPs have been fabricated into foams which 
exhibit increased permeability and volume expansion relative to neat SMPs. Ultra low 
density, highly crosslinked SMP foams incorporating polyurethane chemistry have been 
widely studied for multiple biomedical applications including embolic devices for 
cerebrovascular aneurysms, thrombectomy retrieval, and stents.72, 73 Altering polymer 
chemistries allows for modulation of the transition temperatures and rate of recovery.  
Singhal et al. reports the ability to control the polyurethane SMP foam actuation rate 
which naturally exhibits a passive shape memory behavior due to plasticization in 
water.74 Furthermore, the 3D scaffold fabrication technique employed provides further 
ability to modulate properties and delivery method. Zhang et al. have illustrated the bone 
grafting potential of polycaprolactone (PCL) – polydimethylsiloxane (PDMS) block 
copolymer SMPs fabricated via an altered particulate leaching process with 
polydopamine coating.62 The authors illustrated the ability to tune pore size, porosity, 
compressive modulus, and degradation rate by altering the length of the PDMS chains.75 
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SMPs have been utilized in the organic phase of high internal phase emulsions resulting 
in highly porous foams with good shape memory behavior.76 Currently, it is unclear 
whether encapsulated cells could remain viable under shape programming conditions 
including non-physiological temperatures and large shear forces. Also, their ability to 
integrate with native tissue on the nanoscopic scale remains to be shown. Furthermore, 
irregularities in the expansion may result in heterogeneous, unexpected properties. Much 
of this work employs shape memory behavior at temperatures exceeding 37ºC reducing 
the ability to use them as materials that set at physiological temperature. 
1.3.2.6 Hydrogels  
Hydrogels are polymer networks that swell in water to 1000X their dry weight. 
These gels are advantageous for tissue engineering and drug delivery applications due to 
their similar properties to soft tissue, ability to incorporate biomolecules without 
solubility constraints, and encapsulate human cells and maintain their viability.49, 63, 77-81 
Commonly natural polymers (collagen, gelatin, fibrin, glycosaminoglycans, alginate, and 
agarose) and synthetic polymers such as poly(ethylene glycol) (PEG) modified with 
integrin binding sites are utilized for tissue engineering applications.82-84 Many groups 
have shown bone regeneration in vivo with engineered hydrogels.84 However, these 
materials will not be able to withstand physiological loading without additional fixation 
which may cause stress shielding and reduced healing in some applications. 
1.3.3 Polymerized High Internal Phase Emulsions (PolyHIPEs) 
 The template polymerization of a high internal phase emulsion results in highly 
porous scaffolds that have the potential to match the properties of cancellous bone as 
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seen in Figure 1.1. High internal phase emulsions are dictated by the internal phase 
composing ≥ 74% of the total volume. For the past 25 years, researchers have 
investigated the use of polyHIPEs as tissue engineered scaffolds.   Table 1.2 depicts the 
range of polyHIPE compositions utilized, their respective pore and interconnect sizes, 
and compressive properties achieved.   
 
 
 
Figure 1.1. Scanning electron micrograph of representative polyHIPE scaffold47 (A) 
compared to image of cancellous bone micro-architecture85 (B) 
 
 
A specific class of emulsions known as pickering emulsions are stabilized by 
solid particles which adsorb to the oil-water interface rather than a molecular 
surfactant.86 Multiple groups have successfully fabricated and characterized water-in-oil 
(w/o) pickering polyHIPEs utilizing both titania and silica nanoparticles.87-90 In reference 
to polyHIPEs for bone regeneration, the preferential location of self-assembled particles 
at the pore wall in direct contact with encapsulated MSCs is beneficial for providing a 
bioactive component that could be utilized for osteoblast differentiation. Recently, 
hydroxyapatite nanoparticles have been utilized to stabilize o/w and w/o/w emulsions as 
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a method to coat polymeric microspheres.90 Therefore, it’s possible to utilize 
osteoinductive particles which self-assemble at the organic-aqueous interface to signal 
differentiation of encapsulated hMSCs. Recently a styrene-based polyHIPE 
 
 
Table 1.2. Selected polyHIPE compositions and respective pore diameter, 
interconnect size and compressive properties 
Materials Surfactant 
Pore 
Diameter 
(µm) 
Interconnect 
Size (µm) 
Compressive 
Properties (MPa) Ref 
PS, DVB Span 80 73-90 16-26 NA 91 
  40-100 15-30 NA 47 
  20-45 1-16 0.007-12 92 
  5-100 NR 3-110 93 
PS, DVB, THF Span 80 5-100 1-5 NA 94 
  35-104 11-26 NA 95 
PS, DVB, 
Toluene 
Span 80 10 NR NA 96 
DVB, EVB Span 80 20-30 0.65-2.55 NA 97 
PS, PMMA, 
PLA 
Span 80 
 Span 85 
 Tween 85 
Synperonic 
PE L121 
5-20 NR NA 98 
PCL-vinyl Span 80 
Span 85 
Tween 80 
Synperonic 
PE L121 
5-100 NR NA 99 
PCL, tBA, DVB Span 80 5-3000 0.2-2 0.012-0.56 100 
PCL-triol, HDI, 
THF 
PGPR 4125 5-100, 
CO2=1000 
0.1-10 0.012-0.5 101 
HA polyHIPE NR NR NR NA 102 
PPF, PFDA, 
Toluene 
Span 80 10-400, 
>500 
2-5 NA 103 
Hydrogel—
polyHIPE 
Hydroxyapatite 
Span 80 100 NR NA 104 
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system (Alvetex®) has been commercialized for use as a routine 3D cell culture 
substrate illustrating the capability of polyHIPEs to promote cell viability and 
proliferation.105  
1.3.3.1 Tailoring PolyHIPE Pore Architecture  
Extensive research has focused on the effects of specific compositional and 
processing variables on polyHIPE pore size and interconnectivity. Emulsion stability at 
the gel point dictates the pore size. Thus, all factors affecting emulsion stability 
contribute to the resulting polyHIPE pore architecture. Williams illustrated the 
importance of surfactant concentration on pore size.106 Since the early work by 
Williams, many other studies have further emphasized surfactant concentration as the 
variable having the largest affect on pore size. Interconnected pore architecture is 
achieved by the tearing of the thin wall between adjacent droplets and is therefore 
modulated by the wall thickness and densification forces during crosslinking.107-110 This 
process that occurs during curing is advantageous over other techniques in which post-
fabrication reticulation must be performed to create interconnected porosity.74  
1.3.3.2 Modulating PolyHIPE Degradation Rate  
Traditionally, polyHIPE systems have been fabricated with styrene incorporating 
divinyl benzene as a crosslinker. Although these polyHIPEs exhibit excellent 
interconnected architecture, these monomers are non-biodegradable limiting their use as 
tissue engineered scaffolds. Biodegradability was introduced via polyurethanes and 
unsaturated polyesters.101, 103 Furthermore, a recent push in the biomaterials community 
has illustrated enhanced hydrolytic degradation rates by the incorporation of thiols in 
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acrylate and methacrylate systems. Recently, a couple of research groups have fabricated 
thiol-ene polyHIPEs111, 112 and illustrated the ability of these biodegradable scaffolds to 
support human keratinocyte growth.113 
1.3.3.3 Bioactive PolyHIPEs  
Recent work on developing polyHIPEs with enhanced bioactivity has focused on 
the use of biopolymers and/or covalently attaching bioactive peptides post-
fabrication.114, 115 Oil-in-water (O/W) HIPEs were fabricated utilizing the 
polysaccharides dextran and pullulan and resulted in excellent interconnected scaffolds 
which promoted retinal cell adhesion.114 Polypeptide-grafted styrene-based polyHIPEs 
were fabricated illustrating the potential to surface modify monoliths with any growth 
factor or signaling peptide of interest.115 Although, these systems produce well 
interconnected scaffolds with tunable pore sizes and bioactivity, all post-fabrication 
techniques eliminate the potential as an injectable material able to space-fill any 
irregularly shaped defect. Furthermore, biopolymeric scaffolds generally exhibit inferior 
mechanically properties relative to highly crosslinked synthetic networks thus the 
importance for utilizing synthetic polymers in HIPE systems.   
1.4 Bioactive Factors to Enhance Bone Regeneration 
1.4.1 Calcium Phosphate Particles  
Calcium and phosphate ions are essential for bone mineralization and important 
for the signaling processes that occur for healing. In this manner, incorporating calcium 
phosphate-based particles into biomaterials is a means of providing cells cues to promote 
osteogenesis. Depending on the temperature, number of impurities, and presence of 
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water, calcium phosphates can occur in multiple different phases.116 A range of 
bioactivities and degradation rates exist for calcium phosphates depending on the Ca/P 
ratio, crystallinity, and phase purity. Table 1.3 displays a selection of calcium phosphate 
formulations and their respective calcium/phosphate molar ratios and solubility in 
physiological pH (~7.4). The size, shape, and resulting dissolution rate dictates the  
 
 
Table 1.3. Range of calcium phosphate formulations and properties achieved by 
using calcium phosphate particles with different Ca/P ratios1 
Calcium Phosphate Formulation Ca/P Molar Ratio Solubility Product 
Monocalcium phosphate (MCP) 0.5 7.2 X 10-2 
Amorphous calcium phosphate 
(ACP) 
1.2-2.2 varies due to 
metastable nature 
β-Tricalcium phosphate (β-TCP) 1.5 1.25 X 10-29 
Hydroxyapatite 1.67 2.35 X 10-59 
 
 
ability of cells to engulf ions and respond with matrix formation.117 Davison et al. 
discuss importance of calcium phosphate submicrostructure on inflammatory response in  
vivo.118 
1.4.2 Demineralized Bone Matrix (DBM) 
 In the early 19th century, it was hypothesized that de-calcified bone could be 
utilized to provide antimicrobial healing in bone defects. Urist and colleagues in 1965 
published initial work showing matrix-induced bone formation after implanting bone 
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matrix in muscle.119 This work confirmed the hypothesis that by providing decalcified 
bone matrix, the tissue will heal via an autoinduction mechanism initiated by histiocytes 
(multinucleate macrophages) that detect degraded bone in the implant site and signal 
differentiation and repair. Furthermore, the collagenous DBM matrix sequesters 
important growth factors for MSC differentiation including bone morphogenetic proteins 
(BMPs).120 Similar to any matrix component, the amount and presentation of biological 
agents dictates certain physiological results. Zhang et al. illustrated the effects of DBM 
particle size on osteoinductivity indicating particles ranging from 500 – 710 µm resulted 
in maximum calcium deposition in an ectopic bone growth mouse model.121 
Additionally, they determined the effect of various levels of matrix decalcification and 
found that partially decalcified matrix elicited the highest increase in osteogenesis using 
alkaline phosphatase activity as the marker suggesting that too much calcified matrix 
hinders the signaling for and/or new mineralization. Smaller amounts of residual calcium 
nodules provide nucleation sites for new mineralization when implanted. Furthermore, 
the ability of calcium ions to block the release of proteins such as BMPs suggests that a 
threshold value of residual calcium exists in which to promote new matrix formation 
while allowing for the release of growth factors such as BMPs to signal for osteogenic 
differentiation and new bone formation.121  
1.5 Benefit of MSC Delivery in Bone Regeneration  
The advancements in stem cell biology and effective protocols for culturing 
multipotent cells have provided the opportunity for testing and analyzing the advantages 
of delivering autologous stem cells to injured sites via 3D tissue engineered scaffolds.  
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Recent studies have illustrated enhanced bone regeneration with the delivery of bone 
marrow derived mesenchymal stem cells.122-125 Petite et al. showed complete bridging of 
a sheep segmental defect with the delivery of MSCs compared to fresh bone marrow and 
the blank coral scaffold.123 In accordance with the tissue engineering paradigm, the 
incorporation of mesenchymal stem cells which are equipped to promote osteogenesis 
into a biodegradable, porous bone graft will increase the regeneration rate by imitating 
the body’s natural healing process. 
1.5.1 Autologous Stem Cell Delivery in a Rigid Bone Graft  
The knowledge and techniques developed by stem cell biologists has greatly 
increased the ability to extract, expand in in vitro culture to acquire enough cells, and 
deliver viable autologous adult stem cells. The FDA has cleared multiple indications for 
the use of adult stem cells for treatment of multiple sclerosis, multiple ischemia 
pathologies, motor neuron disease, and blood and immune disorders including certain 
cancers.126, 127 Unfortunately, these cells often flow or migrate away from the application 
site too quickly and do not remain for the time necessary for treatment or healing to 
occur, therefore necessitating a biomaterial delivery system for these cells to remain 
viable and available for direct healing at the defect site. The earliest work on cell 
encapsulation employed natural polymer-based (collagen, fibrin, agarose, and alginate) 
hydrogels to provide an extracellular-like matrix to promote cell adhesion and 
proliferation.83, 84, 128 Burdick et al. illustrated the ability to stimulate bone growth and 
matrix formation of osteoblasts cultured in PEG hydrogels with covalently attached 
RGD adhesive peptides covalently incorporated.84 Although these systems can be 
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engineered to have specific integrin binding sites and easily serve as encapsulation 
vehicles for the delivery of viable cells, they lack the requisite mechanical properties to 
support bone regeneration. Furthermore, a rigid, 3D scaffold that promotes MSC 
viability, proliferation, and osteogenic differentiation has the potential to enhance bone 
regeneration by providing a network that can withstand physiological loading known to 
stimulate osteogenesis.  
1.6 Summary and Approach 
Although autografts and allografts provide the necessary cues to promote 
osteogenesis, the high variability and reduced availability of healthy tissue justify the 
need for a reproducible, highly available graft. Calcium phosphate bone fillers provide 
the necessary mineral components to drive osteogenic differentiation but lack the 
porosity and compressive toughness to promote long term viability at the defect. 
Utilizing a synthetic approach to fabricate highly tunable tissue engineered scaffolds 
addresses the issue of poor availability and reliability. Furthermore, the ability to 
incorporate bioactive components and stem cells facilitates a system that promotes 
osteogenesis similar to native tissue. The template polymerization of high internal phase 
emulsions provides a highly tunable technique to produce injectable bone grafts with 
compressive properties comparable to cancellous bone with the added benefit of 
autologous stem cell encapsulation to promote regeneration directly at the defect site.  
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CHAPTER II  
MODULATING INJECTABLE POLYHIPE PORE AND INTERCONNECT SIZE* 
2.1 Introduction 
For decades, tissue engineers have illustrated the importance of 3D biomaterial 
scaffolds in healing by providing a matrix to direct tissue regeneration. These scaffolds 
stimulate neotissue formation by sequestering vital growth and transcription factors, 
providing an interconnected network to facilitate nutrient and waste transport, exhibiting 
compressive properties matching native tissue, and demonstrating a degradation profile 
that mirrors the healing rate in vivo. Polymerized high internal phase emulsions 
(polyHIPEs) are a unique fabrication technique that is currently being studied for their 
utility as tissue engineered scaffolds. High internal phase emulsions are dictated by an 
internal phase volume fraction greater than 74%. Polymerization of the continuous phase 
of a high internal phase emulsion (polyHIPE) results in a highly porous, interconnected 
foam. Multiple compositional and processing variables have been determined to affect 
emulsion stability which dictates the resulting pore architecture and consequent 
mechanical properties. Through manipulation of these variables, a range of pore sizes, 
porosities, compressive properties, and rheological properties can be achieved,  
____________________ 
 
* Reprinted with permission from “Injectable PolyHIPEs as High-Porosity Bone Grafts,” by Robert S. 
Moglia, Jennifer L. Holm, Nicholas A. Sears, Caitlin J. Wilson, Dawn M. Harrison, and Elizabeth 
Cosgriff-Hernandez, Biomacromolecules 2011, 12 (10), 3621-3628. Copyright (2011) American Chemical 
Society. 
Reprinted with permission from “Achieving Interconnected Pore Architecture in Injectable PolyHIPEs for 
Bone Tissue Engineering,” by Jennifer L. Robinson, Robert S. Moglia, Melissa C. Stuebben,  et al, Tissue 
Engineering Part A 2014, 20 (5-6), 1103-1112. Copyright (2014) Mary Ann Liebert, Inc. 
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illustrating the utility of polyHIPEs for hard and soft tissue repair.47, 91-99, 101-104, 106, 114, 
129-137   
A unique characteristic of the polyHIPE system as a tissue engineered graft is its 
mayonnaise-like viscosity prior to cure which is suitable for injection and retention at the 
defect site. An injectable scaffold that fills irregularly-shaped defects and integrates with 
host tissue can enhance healing and reduce inflammation.138 Initially, styrene-based 
polyHIPE systems were studied due to the established control of the interconnected pore 
architecture. Bioactive components were successfully introduced into styrene-based 
polyHIPEs to provide substrates that promoted osteoblast and neuronal cell adhesion and 
proliferation.47, 94, 139 Although these polyHIPEs are valuable as 3D cell culture 
substrates, these materials are not biodegradable or injectable which limits their use as 
tissue engineered scaffolds. Biodegradability was introduced into polyHIPEs by the 
substitution of unsaturated polyesters into systems that still contained non-biodegradable 
crosslinkers or diluents.92, 99, 140 Subsequently, fully biodegradable systems were 
achieved by eliminating styrene and utilizing polyurethane and fumarate chemistries.103, 
141 Although these compositions were biodegradable, the necessity of a toxic diluent and 
cure temperatures at or above 60°C rendered them non-injectable. An injectable 
polyHIPE system requires low viscosity macromers for HIPE formation without the 
need for a toxic diluent and reaction kinetics permitting crosslinking in situ.  
Our lab has developed the first biodegradable and injectable HIPE system based on 
propylene fumarate dimethacrylate (PFDMA) macromers.142 These polyHIPEs were 
fabricated without a toxic diluent and successfully cured at 37°C. Traditionally, selection 
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of HIPE surfactants has been based on trial and error and historical precedence. Rational 
design was utilized to determine effective surfactants to stabilize PFDMA HIPEs based 
on structural features and predictors. The fabrication of these injectable polyHIPEs was a 
great advancement for bone tissue engineered scaffolds; however, the ability to tune pore 
architecture must be illustrated. PolyHIPE pore size is dictated by the internal phase 
droplet size at the gel point. The 3D pore architecture largely affects the compressive 
properties of the monolith indicating the importance of developing a system with 
tunable, homogenous pore sizes. This work demonstrates the ability to utilize surfactant 
concentration and mixing speed to modulate injectable HIPE emulsion stability and 
thereby tune pore sizes.  
Interconnected porosity is vital in tissue engineered scaffolds to promote the 
transport of essential nutrients to cells. Recent work by Madden et al. highlighted the 
importance of interconnectivity for cell migration and nutrient/waste transport in 
scaffolds with small pore sizes. Human embryonic stem cell-derived cardiomyocytes 
seeded on bimodal scaffolds with interconnected pores ranging from 30 – 40 μm were 
viable for at least two weeks to a depth of 300 µm into the construct.49 Marcacci et al. 
reported that porosity and interconnectivity was also of critical importance in the 
vascularization and healing of a bone segmental defect clinical trial.143 Therefore, 
interconnectivity is a key design criterion in the development of an injectable polyHIPE 
system to support full healing in vivo.  
 In the polyHIPE system, interconnects, or windows between discrete pores, form 
at the gel point from rupture of the thin walls between droplets.144 This phenomenon is 
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dependent on both wall thickness and macromer densification forces from volume 
contraction during conversion of monomer to polymer. Varying the wall thickness and 
densification forces can result in film breakage if the contractile forces are large enough 
to strain the film to failure. Diluents and monomers utilized in the majority of past 
polyHIPE systems most likely enhanced the interconnectivity by decreasing wall 
thickness and increasing the magnitude of densification forces, respectively. Recently, 
the Silverstein group published studies describing the effect of the locus of initiation on 
pore architecture and properties.87, 109, 110, 145 The authors proposed that organic-phase 
initiation resulted in larger, spherical, interconnected pores and an increased loss 
modulus relative to aqueous-phase initiation.110 However, a mechanistic description of 
the effect of locus of initiation on the resulting macromer densification forces and the 
corollary effect on interconnect formation was not described. 
To this end, we have developed a biodegradable and injectable polyHIPE system 
with readily tunable pore sizes, interconnected pore architecture, compressive properties, 
injection parameters, and stable storage capabilities for use an off-the-shelf bone graft. 
The majority of the work is based on propylene fumarate dimethacrylate (PFDMA) 
macromers which have a suitable viscosity for HIPE formation and reactive 
methacrylate end groups which enable in situ crosslinking into rigid monoliths at 37˚C. 
Furthermore, fumarate-based polymers have shown great promise as bone grafts with 
established osteoconductivity in vivo.146-148 The ability to synthesize a fully 
biodegradable polyHIPE without a toxic diluent that can also cure at physiological 
temperatures is an important adaptation of emulsion templating. Parameters such as 
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surfactant concentration, mixing speed, and the phase in which initiation occurs were 
utilized to generate closed vs. open-pore scaffolds with pores ranging from 2 – 29 µm. A 
model system using ethylene glycol dimethacrylate macromers illustrated the potential 
of a hydrophilic polymer to promote Ostwald ripening and increase pore sizes from 50 – 
200 µm. The potential of injectable PFDMA polyHIPEs to be stored at reduced 
temperatures and then thawed before implementation as a bone graft was evaluated. 
Additionally, the effects of precure, storage, and injection on polyHIPE pore 
architecture, work time, and set time were also characterized. Finally, the resulting 
compressive moduli and strength values were evaluated over the course of two weeks. 
Overall, these studies highlight the ability to use multiple compositional variables and 
processing techniques to generate injectable and biodegradable PFDMA polyHIPEs with 
a usable range of pore sizes, compressive properties, cure times, and deployment 
options. This fundamental understanding of mechanisms that dictate HIPE stability and 
resulting properties is vital in rationally designing monoliths to guide mesenchymal stem 
cell proliferation and differentiation into functional osteoblasts to lay down healthy bone 
matrix and stimulate full healing in bone defects. 
2.2 Materials and Methods 
2.2.1 Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Palsgaard (Morris 
Plains, NJ).  All other chemicals were purchased and used as received from Sigma 
Aldrich (Milwaukee, WI) unless otherwise noted.  
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2.2.2 PFDMA Synthesis 
PFDMA was synthesized in a two-step process adapted from Timmer et al.149 
Briefly, propylene oxide was added dropwise to a solution of fumaric acid and pyridine 
in 2-butanone (2.3:1.0:0.033 mol) and refluxed at 80°C for 16-18 hours. Residual 
propylene oxide and 2-butanone were removed by distillation, residual acidic byproducts 
and water were removed with washing, and the product was dried under vacuum. The 
diester bis(1,2 hydroxypropyl) fumarate product was then end-capped with methacrylate 
groups in an addition process with triethylamine (TEA) and methacryloyl chloride 
(MAC). The molar ratios of the diester, MAC, TEA were 1:2.1:2.1, respectively. 
Hydroquinone was added at a molar ratio of 0.008:1 to diester to inhibit crosslinking 
during the synthesis. The reaction was maintained below -10˚C to reduce undesirable 
side reactions and stirred vigorously overnight under a nitrogen blanket. The product 
was washed overnight in 2 M potassium carbonate to neutralize methacryloyl chloride 
after which the PFDMA was passed through a chromatography column loaded with 
alumina at a 9:1 molar ratio alumina:TEA to remove any residual TEA and methacrylic 
acid. The product was then washed in deionized water to remove any alumina and 
subjected to a brine wash and stirred over anhydrous sodium sulfate to remove water. 
The PFDMA product was dried under vacuum and the structure confirmed using H 
NMR (300 MHz, CdCl3) δ 1.33 (dd, 3H, CH3), 1.92 (s, 3H, CH3), 4.20 (m, 2H, -CH2-), 
5.30 (m, 1H, -CH-), 5.58 (s, 1H, -C=CH2), 6.10 (s, 1H, -C=CH2), 6.84 (m, 2H, -
CH=CH-). The integration ratio of methacrylate protons to fumarate protons in the 1H 
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NMR spectra was used to confirm > 90% functionalization for all macromers prior to 
polyHIPE fabrication. 
2.2.3 EGDMA Inhibitor Removal 
The EGDMA was passed through a column containing alumina oxide using high 
air pressure to remove the monomethyl ether hydroquinone inhibitor and collected in a 
round bottom flask. 
2.2.4 PolyHIPE Fabrication  
HIPEs were prepared using the FlackTek Speedmixer DAC 150 FVZ-K. Briefly, 
PFDMA was mixed with the surfactant PGPR in the Speedmixer cup prior to 
emulsification. The PGPR concentrations used in this study were 5, 10, 15, and 20 wt%. 
For studies investigating the effects of surfactant concentration and mixing conditions, 
the aqueous solution of calcium chloride (1% v/v), ammonium persulfate (5 wt %) and 
deionized water was then added to the organic phase in the speedmixer cup. The calcium 
chloride was used to prevent Ostwald ripening while the ammonium persulfate initiated 
radical crosslinking of the macromer chains. HIPEs were then transferred to a 37°C 
aluminum bead bath for 12 hours to facilitate cross-linking. The resulting polyHIPE 
foams were placed under vacuum for 24 hrs to remove water prior to characterization. 
The polyHIPE fabrication process is illustrated in Figure 2.1. For the studies 
looking at the effect of poly(ethylene glycol) molecular weight and concentration and 
temperature effects, both PFDMA and EGDMA HIPEs were made to elucidate the 
effects within HIPEs of differing viscosities. The aqueous phase was comprised of water 
and 3 w/v% PEG with one of the following molecular weights: 200, 300, 400, 2k, 6k, 
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10k, or 35k. Calcium chloride was not added to the aqueous phase as this electrolyte is 
utilized to hinder Ostwald ripening and could therefore negate any effect from the PEG. 
For studies looking at the effect of the locus of initiation on pore architecture, PFDMA  
 
 
 
Figure 2.1 Schematic of the process to fabricate a polymerized high internal phase 
emulsion. A) The emulsion is comprised of a hydrophobic organic phase and an aqueous 
phase. B) HIPE is defined by the aqueous volume phase greater than 74% and exhibits a 
whipped, mayonnaise consistency prior to cure. C) PFDMA crosslinks at 37°C locking 
in the emulsion geometry creating a polyHIPE with high porosity. 
 
 
was first mixed with 5 wt% of the organic-phase soluble initiator, benzoyl peroxide 
(BPO), and 5 wt% PGPR prior to emulsification. Once thoroughly mixed, the aqueous 
solution of calcium chloride (1 wt%) and deionized water was then added to the organic 
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phase (75% v) in six additions and mixed at 500 rpm for 2.5 minutes each. HIPEs were 
transferred to a 37°C aluminum bead bath to facilitate crosslinking overnight. To 
evaluate the effects of locus of initiation on pore architecture, polyHIPEs were also 
fabricated with 5 wt% ammonium persulfate (APS), the aqueous-phase soluble initiator, 
added to the aqueous solution prior to emulsification with the organic phase. Initiator 
concentrations were calculated based on the organic phase weight and kept constant 
between the two systems. This results in a relatively higher initiator concentration in the 
organic phase (5 wt% BPO to total organic phase) compared to initiator concentration in 
the aqueous phase (1.66 wt% APS to total aqueous phase).  
2.2.5 Pore and Interconnect Size Characterization 
SEM (JEOL 6500) was utilized to image all polyHIPEs and determine average 
pore and interconnect size for pre-treatment and storage studies. PolyHIPEs were 
subjected to vacuum drying for 72 hours to remove water prior to pore architecture 
characterization. Circular specimens from three separate polyHIPE specimens were 
sectioned into quarters, fractured at the center, coated with gold, and imaged in a rastor 
pattern yielding five images. Pore size measurements were completed on the first ten 
pores that crossed the median of each 1000X magnification micrograph. Average pore 
sizes for each polyHIPE composition are reported (n=150). A statistical correction was 
calculated to account for non-perfect spherical pores, ℎ2 = 𝑅2 − 𝑟2,  where R is the void 
diameter’s equatorial value, r is the diameter value measured from the micrograph, and h 
is the distance from the center. The average diameter values were multiplied by this 
correction factor resulting in a more accurate description of pore diameter.95 To calculate 
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interconnect sizes, three median lines were drawn on each image, and the first ten 
interconnects located in pores crossing each of these lines was counted. Average 
interconnect sizes for each polyHIPE composition are reported (n=150). 
2.2.6 Compressive Testing 
The change in polyHIPE compressive properties over time was investigated to 
determine the maximum values for a 5 wt% BPO polyHIPE. The PFDMA HIPE was 
split into five centrifuge tubes and cured at 37°C for 1, 3, 7, 10, and 14 days prior to 
mechanical testing. ASTM D1621-04a was utilized to determine the compressive 
modulus and strength of the polyHIPEs.150 Each polyHIPE specimen was sectioned into 
three disks with a 3:1 diameter to height ratio using an Isomet® saw (Buehler) and 
compressed using an Instron 3300 at a strain rate of 50 µm/s. The compressive modulus 
was calculated from the slope of the linear region after correcting for zero strain and the 
compressive strength was identified as the stress at the yield point or 10% strain, 
whichever point occurred first. Reported moduli and strength data were averages of the 
three disks for each time point tested (n=15).  
2.2.7 Pre-treatment and Storage Studies  
The potential of injectable PFDMA polyHIPEs to be stored at reduced 
temperatures and then thawed prior to implementation as a bone graft was evaluated. 
HIPEs fabricated with 5 wt% BPO were split into six 5 ml syringes and subjected to 
either 20°C or 37°C, stored for one week at 4°C, injected, and cured. HIPEs were also 
subjected to pre-treatment heat conditions prior to storage in order to promote 
crosslinking and reduce cure time in vivo. The duration of pre-treatment time was 
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investigated for 1, 2, and 6 hours at 20°C and 37°C. Time points for the pre-treatment 
studies were determined as the hourly times that allowed for initial crosslinking before 
the gel point was reached. The specific storage and pretreatment conditions are detailed 
in the table found on page 51. This study was repeated for a total of three polyHIPE 
specimens in each condition. 
2.2.8 Statistical Analysis 
The data are displayed as mean ± standard deviation for each composition. A 
Student’s t-test was performed on the compressive data to determine any statistically 
significant differences between compositions. Tests for set time and compressive 
properties were carried out at a 90% (p < 90%) and 95% confidence interval (P<0.05), 
respectively. 
2.3 Results and Discussion 
2.3.1 PFDMA Synthesis and Analysis 
 PFDMA was synthesized by the two-step reaction described previously. The 
first step produced a diester intermediate, bis-(1,2-hydroxypropyl) fumarate, which was 
then functionalized with methacrylate endgroups, Figure 2.2.  Following purification, 
the structure of the resulting PFDMA product was confirmed with 1H NMR. The 
integration ratio of methacryloyl protons to fumarate protons in the 1H NMR spectra, 
Figure 2.3, confirmed the structure of PFDMA as a single fumarate unit with two 
terminal methacrylate groups. The average functionalization was calculated to be ~83%. 
The methacrylate and fumarate groups provided sites for radical crosslinking of the 
macromer to permit cure of the HIPE at physiological temperatures. Furthermore,  
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Figure 2.2. Molecular structure of (A) bis (1,2 hydroxypropyl) fumarate and (B) 
PFDMA. 
 
 
 
Figure 2.3. Nuclear magnetic resonance spectrum of PFDMA. 
 
 
fumarate-based bone grafts have shown promising osteoconductivity results in vivo.146-
148 The resulting macromer had a sufficiently low viscosity (0.125 Pa·s) and 
hydrophobicity to permit HIPE formation. 
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2.3.2 Injectable Porous Scaffolds  
Stable PFDMA HIPEs were incubated at 37°C to initiate radical crosslinking of 
the unsaturated double bond of the methacrylate groups. The resulting polyHIPE 
monoliths exhibited ~75% porosity and an average compressive modulus and strength of 
33 and 5 MPa, respectively. SEM analysis was utilized to determine pore size and 
morphology. Polymerization of the continuous phase of the HIPE locked in the emulsion 
geometry resulting in a high-porosity foam with a closed-pore morphology and average 
pore size ranging from 4 – 29 µm. These studies represent an important milestone in the 
development of an injectable bone graft. Specifically, these polyHIPEs utilize a 
biodegradable and osteoconductive polymer, have a suitable pre-cure viscosity for 
injection; and cure at physiological temperatures to a rigid, high-porosity monolith. The 
potential utility of this new polyHIPE system as an injectable bone graft is illustrated in 
Figure 2.4.  
 
 
 
Figure 2.4. Injectable PFDMA polyHIPEs can be used in situ to space fill complex 
defects without the need for expensive CAD software. 
 
 
1. Inject HIPE to fill 
irregular defects
2. Polymerizes at body temperature, 
forming a high porosity bone graft 
37°C
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2.3.3 Effect of PGPR Concentration on Pore Architecture  
Given that the polyHIPE architecture is dictated by the emulsion geometry prior 
to cure, modulation of emulsion stability may be used to tune the resulting polyHIPE 
architecture. This requires a brief review of the thermodynamics involved in both 
emulsion formation and phase separation. The increase in surface energy of an emulsion 
compared to the non-emulsified components (ΔW) is a product of both the interfacial 
energy (𝜎) and the change in surface area (ΔA) upon emulsification.  
 ∆𝑊 = 𝜎 ∙ ∆𝐴 
ΔW is the free energy of the interface and corresponds to the reversible work 
brought into the system during emulsification. The magnitude of ΔW can be considered 
a measure of the thermodynamic instability of the emulsion and drives phase separation 
as a means to decrease ΔA. From this relationship, it is evident that ultimate stability 
against coalescence processes is only achieved if σ approaches zero. The surfactant’s 
role during emulsification is to reduce this interfacial tension and form a barrier between 
the two phases.  
Two relationships relevant to polyHIPE architecture can be inferred from this 
discussion: 1) an increase in interfacial tension (↑𝜎) will increase the rate of droplet 
coalescence due to an increase in ΔW; 2) an increase in interfacial tension (↑𝜎) will 
correspond to larger initial droplet sizes (↓ ΔA) for a given ΔW.  It follows that the 
surfactant which directly impacts interfacial tension can be used to tune pore sizes by 
changing the initial droplet size and/or the rate of droplet coalescence prior to cure. To 
this end, Williams et al. studied the effect of surfactant concentration on both pore size 
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and wall thickness between droplets.93 It was reported that a reduction in surfactant 
concentration could be used to increase pore size by destabilizing the HIPE. In addition, 
an increase in surfactant concentration was found to decrease wall thickness and induce 
pore opening upon polymerization. We hypothesized that HIPE stability could be 
modulated by changing the surfactant concentration to achieve a range of polyHIPE pore 
sizes and an open-pore morphology. PGPR concentrations from 5 to 40 wt% were 
utilized to investigate the effect of surfactant concentration on polyHIPE pore 
architecture. SEM analysis of polyHIPE monoliths was conducted to quantify pore and 
interconnect size using the 10.7 pixels/µm ratio at 1000x, Table 2.1. Decreasing the 
concentration of PGPR from 20 to 5 wt% was found to increase average pore diameter in 
PFDMA polyHIPEs (6 to 29 µm), Figure 2.5. A narrowing of pore size distributions 
with increasing surfactant concentration was also observed, Figure 2.6.  
 
 
Table 2.1. The effect of surfactant concentration on polyHIPE architecture 
Surfactant (wt%) Porosity (%) Average Pore Diameter (µm) 
5 75.1 ± 0.4 29 ± 19 
10 75.1 ± 0.3 21 ± 11 
15 75.1 ± 0.1 14 ±   8 
20 74.1 ± 0.1  4 ±   2 
Gravimetric porosity, N = 3, average ± standard deviation. Average pore 
measurements from image analysis of scanning electron micrographs, N = 150, 
average ± standard deviation. 
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Figure 2.5. Scanning electron micrographs (A,B,C,D) of PFDMA polyHIPEs with 
increasing surfactant concentrations. It can be seen that pore sizes decrease as PGPR 
concentration increases from 5-20 wt%. 
 
 
 
Figure 2.6. Distribution of pore sizes for 75/25 polyHIPEs with varied PGPR 
concentrations, mixed at 500 rpm. (A) 10 wt%, (B) 15 wt%, and (C) 20 wt%. Pore sizes 
become more uniform as PGPR content increases. 
 
 
The decreased pore size observed at higher surfactant concentration was 
attributed to a decrease in interfacial tension with a corollary decrease in droplet size, as 
discussed above. Assuming conservation of organic phase volume, this increase in 
surface area also decreases the film thickness between droplets;151 however, this wall 
thinning was insufficient to lead to pore opening in this system. Based on these 
preliminary results, it was hypothesized that increased densification in combination with 
decreasing film thickness would be needed to generate open-pore polyHIPEs. This is the 
subject of current investigation using alternative fumarate-based macromers. A 
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narrowing of the pore size histograms also indicated that a higher surfactant 
concentration resulted in a more uniform pore size, Figure 2.6. Williams et al. reported 
that increased pore size homogeneity was observed with increased surfactant due to a 
reduction in droplet coalescence.93 However, the droplet coalescence observed in these 
studies was characterized by a few large pores surrounded by many smaller pores. As 
illustrated in Figure 2.6, there was a continuum of pore sizes observed rather than the 
more bimodal distribution reported by Williams et al.93 Ostwald ripening has also been 
reported to increase the pore size distribution of polyHIPEs. In this process, diffusion of 
water from smaller droplets to larger droplets causes a more gradual broadening of the 
pore size distribution.95 Both of these processes are affected by the nature and 
concentration of surfactant; however, it is unclear whether droplet coalescence or 
Ostwald ripening is responsible for the observed difference in pore size distribution. 
Based on the histograms alone, it appears that Ostwald ripening may be more 
significant; however, additional studies are needed to make a stronger claim on this 
front. 
2.3.4 Effect of Mixing Speed on Pore Architecture  
Processing parameters such as mixing speed can also be utilized to tune the pore 
architecture through manipulation of the emulsion geometry prior to cure. Revisiting the 
thermodynamic stability of the system yields mechanistic answers for the effect altered 
mixing speed has on pore size and homogeneity. Varying the mixing speed directly 
affects the difference in surface energy of the emulsion relative to the non-emulsified 
components. By adding mechanical energy into the system through mixing, the surface 
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energy of the emulsion is increased yielding a larger change relative to the non-
emulsified components (∆W). This causes an increase in the surface area (∆A) of the 
droplets upon emulsification, assuming low interfacial tension due to surfactant (σ). This 
increase in surface area corresponds with decreased droplet sizes. We hypothesized that 
pore size and homogeneity can be modulated by altering the free energy of the system 
resulting in decreased pore diameters and increased homogeneity with an increase in 
mixing speed. 
Mixing speeds of 500, 1000, and 2000 rpm on the FlackTek Speedmixer™ were 
tested to investigate the effect on pore architecture. Initially, HIPEs with 20 wt% PGPR 
were utilized resulting in minimal change in pore size with an increase in mixing speed 
as seen in Table 2.2. We hypothesized that destabilizing the emulsion with a lower 
concentration of PGPR would result in a larger pore size distribution, thereby clearly 
illustrating the effect of mixing speed. Scanning electron micrographs of both 10 and 20 
wt% PGPR compositions at varying mixing speeds are found in Figure 2.7. A decrease 
in pore size was observed with both 10 and 20 wt% PGPR specimens as mixing speed 
was increased (500 to 2000 rpm). As discussed, the trend was more evident with the 10 
wt% PGPR specimens, Table 2.2, and further illustrates the effect of surfactant on 
emulsion stability and pore architecture. The narrowing of the histograms in Figure 2.8 
from 500 to 2000 rpm indicates a more homogeneous pore size distribution which is 
illustrated in the SEM images. As stated previously, increased surfactant produced an 
increase in pore homogeneity due to decreased surface energy. Combining both mixing 
speed and surfactant had a large effect on pore size homogeneity as observed in Figure  
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Table 2.2. The effect of mixing speed on polyHIPE pore structure with a 
constant volume fraction (75/25) and varied surfactant concentration (10 and 20 
wt% PGPR) 
Mixing Speed (rpm) [PGPR] Average Pore Diameter (µm) 
500 
10 wt% 21 ± 11 
20 wt% 4 ± 2 
1000 
10 wt% 8 ± 4 
20 wt% 3 ± 2 
2000 
10 wt% 4 ± 3 
20 wt% 2 ± 1 
Average pore measurements from image analysis of scanning electron micrographs, N = 
150, average ± standard deviation. 
 
 
 
Figure 2.7. Scanning electron micrographs of PFDMA polyHIPEs fabricated at 
increasing mixing speeds. (A-C) 10 wt% PGPR (A) 500 rpm (B) 1000 rpm (C) 2000 
rpm, (D-F) 20 wt% PGPR (D) 500 rpm (E) 1000 rpm (F) 2000 rpm. A decrease in pore 
size is seen with an increase in mixing speed. 
 
 
2.8 by increasing the surface area of the emulsion and decreasing the interfacial energy 
of the droplets, respectively, to reduce droplet size and coalescence. 
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Figure 4. Scanning electron micrographs of PFDMA polyHIPEs fabricated at increasing mixing speeds: (A-C) 10 wt% PGPR (A) 
500 rpm (B) 1000 rpm (C) 2000 rpm, (D-F) 20 wt% PGPR (D) 500 rpm (E) 1000 rpm (F) 2000 rpm
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Figure 2.8. Distribution of pore sizes for 75/25 polyHIPEs fabricated with 10 (black) 
and 20 wt% PGPR (blue) at 500, 1000, and 2000 rpm. 
 
 
2.3.5 Effect of Poly(ethylene glycol) on Pore Architecture 
Work by Carnachan et al. illustrated the ability to modulate polyHIPE pore size 
via the incorporation of a hydrophilic polymer in the aqueous phase.95 The addition of  
 
 
 
Figure 2.9. Scanning electron micrographs illustrating the effect of PEG molecular 
weight on aqueous phase Ostwald ripening and resulting pore architecture in EGDMA 
polyHIPEs 
 
 
water-miscible poly(ethylene glycol) promotes increased diffusion of water droplets and 
results in Ostwald ripening. Figure 2.9 displays the effect of PEG molecular weight on 
EGDMA polyHIPE pore architecture. An increase in pore size (50 – 200 µm) was 
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observed with an increase in PEG molecular weight with the largest effect at a molecular 
weight of 2k. At molecular weights higher than 2k, a negligible effect was seen which 
may be due to limited diffusion kinetics. No effect was observed in PFDMA polyHIPEs 
due to the increased viscosity of the organic phase providing a physical barrier for phase 
separation. 
2.3.6 Locus of Initiation  
Previous PFDMA polyHIPEs were initiated with the aqueous-phase soluble 
initiator APS and resulted in closed pore foams. Interconnectivity was achieved in this 
study by switching the locus of initiation from the aqueous to organic phase using BPO 
as the radical initiator. The BPO concentration was chosen as the lowest amount that 
produced cured monoliths in the range of 2-3 hours. Because the organic phase 
comprises a quarter of the total HIPE volume in these studies, the amount of BPO 
required to achieve roughly the same cure time among the two systems was one third the 
amount of APS utilized previously. This reduction in initiator concentration decreases  
the possibility that residual initiator leaches out of the material and has cytotoxic effect 
in vivo. The effect of the locus of initiation on interconnect formation is illustrated in 
Figure 2.10. Organic-phase initiation resulted in the formation of interconnects 
compared to the closed-pore morphology from aqueous-phase initiation in the PFDMA 
polyHIPE system. The effect of the locus of initiation on pore interconnectivity has been 
noted previously in the polyHIPE literature.87, 109, 110, 145 However, a mechanistic 
understanding of the process has yet to be discussed. A probable description of  
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Figure 2.10. Scanning electron microscopy micrographs illustrate PFDMA polyHIPEs 
with (A) closed pore morphology from interfacial initiation and (B) open pore 
morphology from organic phase initiation. 
 
 
interconnect formation based on the forces generated during the conversion from 
PFDMA macromer to crosslinked polymer is illustrated in Figure 2.11. The green 
gradient region illustrates the progression of crosslinking from initiation sites. It is 
proposed that the thin film between water droplets in the aqueous-phase initiation system 
is crosslinked resulting in a closed-pore architecture as evident by the location of the 
green region between pores. In organic-phase initiation, the green regions are located in 
the denser pockets where pores are not adjacent to each other. The force of densification 
upon conversion of macromer to polymer results in forces that pull and tear the thin film 
between the pores which is shown as the yellow regions in the figure. This tearing 
results in interconnects or windows between the pores. With this understanding, future  
tuning of interconnect size and frequency may be achieved. Current work is focused on 
increasing densification which is heavily dictated by the size/density of the  
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Figure 2.11. Schematic of the proposed mechanism for interconnect formation 
illustrating the effect of initiation loci on macromer densification forces during cure. 
Organic phase initiation results in sufficient densification forces as the macromer chains 
convert to polymer to tear the thin film between droplets and open pores. Red illustrates 
initiator, yellow illustrates macromer, and green illustrates the loci of initiation and 
regions where crosslinking is occurring. 
 
 
monomer/macromer and altering crosslinking kinetics to further increase interconnect  
size. 
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2.3.7 Compressive Properties 
Compressive modulus and strength values were determined using an Instron 
mechanical testing apparatus on polyHIPEs cured through two weeks. A representative 
stress/strain plot for specimens with a yield point prior to or after 10% strain is shown in 
Figure 2.12. PFDMA polyHIPEs initiated with 5 wt% BPO resulted in compressive 
modulus and strength values increasing through two weeks as illustrated in Figure 2.13. 
It is probable that crosslinking is continuing over time due to the relatively slow reaction 
kinetics at 37°C. Average values recorded at two weeks for compressive modulus and 
strength were 43 ± 12 MPa and 3 ± 0.2 MPa, respectively. These values approach those 
of human cancellous bone of 20-500 MPa46, 152 for modulus and 2-30 MPa153, 154 for 
strength. This data suggests that the compressive strength may continue to increase as 
 
 
 
Figure 2.12. Stress/strain plot illustrating two representative specimens with yield points 
before or after 10% strain with “X” denoting the yield points taken for strain. The dotted 
line indicates 10% strain and the “O” denotes compressive stress taken at 10% strain for 
strength values. 
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indicated by the lack of a plateau in values. Analyzing the compressive properties of 
HIPEs stored for a year at 4°C illustrated maintenance of properties, namely a modulus 
of 47 MPa and strength of 2.2 MPa. ISO standard 5833 for bone cement states a 
requisite ≥ 70 MPa of compressive strength.155 However, materials with compressive 
properties on the low end of human cancellous bone have been shown to encourage new 
tissue growth in animal models in vivo.53, 156 Therefore, it may not be necessary to meet 
these high compressive properties of bone cement in a tissue engineered scaffold that 
will be remodeled to bone. 
 
 
 
Figure 2.13. The effect of time on PFDMA polyHIPE compressive modulus and 
strength. *+° indicate statistically significant differences between respective samples 
p < 0.05 
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2.3.8 Pre-treatment Studies: Effect on Cure Time 
HIPEs were subjected to pre-treatment conditions to promote crosslinking prior to 
injection for reduced cure time in vivo without the need to alter HIPE composition such 
as initiator concentration. Work time is the time available to a surgeon after the onset of 
mixing to manipulate the material without detriment to its properties.157 The work time 
can be determined by the gel point in which the crosslinking in the system is sufficient to 
resist flow.158 The intersection of loss and storage modulus is often utilized to determine 
this gel point of crosslinkable polymers.159 However, in the HIPE system, the storage 
modulus was determined to be larger than the loss modulus throughout the duration of 
testing which was attributed to the HIPE’s viscoelastic behavior. Therefore, the onset of 
the increase in storage modulus determined with DMA was utilized as the work time in 
this study. PolyHIPE set time, or the time required for the material to cure to a solid 
monolith, was approximated using tack-free time as defined in the methods. Work and 
set time values as a function of pre-treatment conditions are located in Table 2.3. Pre-
treatment for one hour at 37°C decreased the work time but not statistically significantly 
compared to the storage control. However, the set time was statistically significantly 
decreased by pre-treating at 37°C for one hour as seen in Figure 2.14.  In these studies, 
pre-treating at 20°C and 37°C had a modest effect on set time. BPO has an average 10 
hour half life at 70°C in benzene.149 Therefore, at 37°C only a fraction of BPO is 
dissociating into radicals, reducing the number of chains able to propagate which results 
in a longer set time. Increasing the reaction kinetics in the system via aqueous phase 
temperatures during HIPE formation and cure temperatures is expected to increase the 
 51 
 
Table 2.3 The effect of storage and injection on polyHIPE microarchitecture, 
work time, and set time. Work time was only determined for the storage control 
and pre-treatment at 37°C composition to estimate the range of time the HIPE 
could be manipulated before injection. 
 
 
 
rate of BPO dissociation thereby increasing the number of propagating chains and 
decrease set time. Studies are currently underway to increase the aqueous phase 
temperature upon addition to the organic phase and pre-treatment temperature to further  
 
 
 
Figure 2.14. The effect of pre-treatment on polyHIPE set time. The specific pre-
treatment and storage conditions are listed in the first and second rows of the axis title, 
respectively. *° indicates statistically significant differences between respective samples 
p < 0.10 
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decrease cure time in vivo. An additional benefit with increased pre-treatment 
temperatures is the ability to decrease initiator concentration without the concern of an 
increased set time. Decreased initiator concentrations may be advantageous to avoid 
negative cytotoxic effects of the radical initiator. 
2.3.9 Storage Studies: Effect on HIPE Stability 
Storage studies were employed to investigate the use of PFDMA polyHIPEs as 
off-the-shelf bone grafts. The envisioned deployment method includes: HIPE fabrication 
and transfer to a sterile syringe, pre-treatment to produce desired properties post 
injection, storage at reduced temperatures, and injection after thawing in the surgical 
suite. To this end, it was essential to determine the effect of storage conditions on 
emulsion stability and resulting pore architecture. Storing PFDMA polyHIPEs at 4°C for  
 
 
 
Figure 2.15. Representative SEMs of PFDMA polyHIPEs after storing unpolymerized 
HIPEs at 4 °C for up to 6 months 
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one year had a negligible effect on the pore and interconnect size as seen in Figure 2.15  
indicating the potential of PFDMA polyHIPEs as off-the-shelf bone grafts. Additionally, 
all pre-treatment conditions resulted in no statistically significant change in pore and 
interconnect sizes again noting the ability to pre-treat, store, and inject these scaffolds 
without affecting the determined pore architecture. It is probable that the current pore 
sizes of injectable PFDMA polyHIPEs are too small for full bone healing in vivo. 
Previous work with ceramic and polymer scaffolds indicated a range of pore sizes from 
75 – 400 µm was necessary for osteogenesis and increased bone formation.160-162 
Previous polyHIPE studies by other investigators have shown a significant increase in 
pore size by heating the aqueous phase to temperatures ranging from 40°C to 80°C prior 
to addition to the organic phase.47, 95 We have recently replicated these results by 
increasing both aqueous phase and pre-treatment temperature and are pursuing ways to 
homogenize the pore size. Future work will focus on fabricating lower viscosity 
polyHIPEs with EGDMA and butanediol dimethacrylate macromers added to the 
organic phase and have preliminary data illustrated increased pore sizes.  
2.4 Conclusions 
The application of emulsion templating in the development of tissue engineering 
scaffolds is a relatively new area of orthopedic research.  In this work, polyHIPEs were 
fabricated without toxic solvents or monomers at cure temperatures appropriate for in 
situ deployment. These new polyHIPEs have potential application as an injectable, tissue 
engineered bone graft. Injectable grafts that are also biodegradable and porous offer 
unique advantages over current alternatives in terms of deployment and tissue 
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integration. The focus of this work was to develop injectable polyHIPEs with tunable 
pore size and interconnectivity. The potential for these scaffolds to be utilized as tissue 
engineered bone grafts was then evaluated by examining injection parameters, 
compressive properties, and stability during storage. By modulating compositional 
parameters (e.g. surfactant concentration, polyethylene glycol molecular weight, 
aqueous vs. organic-phase initiation) and processing parameters (e.g. mixing speed, 
conditions prior to cure, and storage environment) polyHIPEs with a range of pore 
architectures, compressive properties, and set times were produced. In PFDMA 
polyHIPEs, the pore size was increased by decreasing surfactant concentration and the 
mixing speed during fabrication. Adding higher molecular weight PEG to increase 
Ostwald ripening and resulting pore size was demonstrated in EGDMA polyHIPEs 
indicating the potential to use this tool in lower viscosity HIPEs. Interconnectivity was 
introduced to these biodegradable, injectable porous scaffolds by altering the phase in 
which radical initiation occurs. Organic-phase initiation resulted in macromer 
densification forces that facilitated pore opening. In addition to facilitating bone 
ingrowth, this interconnected porosity will also enable the PFDMA polyHIPEs to be 
pursued as rigid cell carriers through the encapsulation of human mesenchymal stem 
cells (hMSCs). Pre-treatment of the materials prior to injection allowed for tuning of 
both work and set times.  Finally, storage of the polyHIPEs for one year at 4°C had a 
negligible effect on pore architecture providing an initial indication of the ability of these 
materials to be utilized as off-the-shelf grafts. With the understanding of how these 
phenomena affect emulsion stability and resulting pore architecture, polyHIPE 
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monoliths can be rationally designed to have a wide range of properties and flexible 
deployment options. Overall, this work highlights the potential of interconnected 
PFDMA polyHIPEs as injectable scaffolds for bone tissue engineering.  
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CHAPTER III 
MODULATING INJECTABLE POLYHIPE DEGRADATION RATE 
3.1 Introduction 
Traditionally, polyHIPEs have been fabricated utilizing styrene and 
divinylbenzene monomers to create highly crosslinked networks within the polymerized 
organic phase.93, 106, 151 While these scaffolds have excellent interconnected pore 
architectures, these monomers are not susceptible to hydrolysis, designating them non-
biodegradable. Biodegradability was introduced into polyHIPEs by the substitution of 
unsaturated polyesters into systems that still contained non-biodegradable cross-linkers 
or diluents.92, 98, 99 Subsequently, fully biodegradable systems were achieved by 
eliminating styrene and utilizing polyurethane and fumarate chemistries.103, 141 The 
introduction of hydrolytically-labile ester and urethane groups in the network allows for 
degradation; however, these degradation profiles are potentially too slow to match that 
of tissue healing. Therefore, introducing β-thioesters into the organic phase of HIPEs 
provides the ability to modulate the hydrolytic degradation rate to better match 
physiological healing rates. 
Recently, work in the Hubbell lab illustrated the highly tunable nature of 
hydrolysis dependent on the proximity of a sulfide group to a hydrolytically labile ester. 
In this work, they illustrated the ability to tune the degradation rate of PEG-based  
hydrogels from days to weeks solely by increasing the distance from the sulfide to the 
ester by a single methylene unit.163 This phenomenon was attributed to the change in 
atomic charge on the carbonyl group. As the number of methylenes between the sulfide 
 57 
 
and the ester decreases, the atomic charge on the carbon atom becomes more positive 
due to the electronegativity of the thiol resulting in increases susceptibility to hydrolytic 
attack. Also, the increase in hydrophilicity with the removal of one methylene may also 
increase hydrolytic degradation rate. This ability to finely tune the hydrolytic 
degradation rate of a synthetic polymer network could be advantageous in injectable 
polyHIPEs for bone tissue engineering. 
Many researchers have probed Michael addition-type reactions to create ideal, 
step-growth crosslinked networks that further modulate hydrolytic degradation rate.163, 
164 Specifically, thiol-ene chemistry, defined as the radical, step-growth polymerization 
involving multifunctional thiols and multivinyl monomers, has been pursued as a means 
to achieve homogeneous, predictable crosslinked networks that have a quick gelation 
rate.165-168 In contrast to the traditional free-radical polymerization of unsaturated vinyls, 
thiol-ene polymerization proceeds in a unique step-growth addition mechanism that is 
facilitated by a free-radical chain transfer process.112, 168 Specifically, the reaction of 
acrylates and methacrylates with thiols has been investigated as a mixed-mode 
polymerization encompassing both the traditional radical polymerization of these 
reactive groups and step-growth of the thiol radical with the unsaturated vinyl.169 This 
specific mixed-mode polymerization allows for the ability to spatiotemporally control 
the crosslinking reactions while maintaining the predictable step-growth polymerization 
mechanisms and tunable degradation rate.169 Additionally, the thiol-vinyl reaction is less 
susceptible to oxygen inhibition resulting in efficient polymerizations in physiological 
environments.169, 170 Translation of this chemistry into biocompatible polymeric network 
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systems has been a focus of Anseth’s and Bowman’s research. Specifically, they have 
investigated the relative reactivities of multifunctional thiols with acrylates and the 
effects on 3D network formation noting the contributions of both the radical 
polymerization of the acrylates and the step-growth reaction of the vinyl with the 
thiol.165, 169, 171-176 Rydholm et al. probed the effect of the concentration of a 
tetrafunctional thiol on network formation, degradation rate, and mechanical properties, 
illustrating an increase in degradation rate due to a decreased network chain length from 
increased chain transfer with thiol.169 Furthermore, they illustrated the ability to use this 
mixed-mode polymerization to achieve fast gelation times without the need for any 
added initiator indicating the potential for enhanced bioactivity and viability of 
encapsulated proteins/biomolecules and cells, respectively.177 This work revolutionized 
the biomaterials field by illustrating the facile nature of creating thiol-acrylate networks 
without the use of solvent and harsh crosslinking conditions. 
In the past four years, multiple groups have fabricated thiol-ene polyHIPEs and 
investigated the effect of acrylate and thiol molecular weights and the number of 
functional groups (i.e. tri vs. tetrafunctionalized) on crosslinking efficiency, elastic 
modulus, and degradation rate.111-113, 178 Furthermore, these thiol-ene polyHIPEs have 
been illustrated as suitable tissue engineering scaffolds that promote human keratinocyte 
growth and proliferation.113 The majority of these past thiol polyHIPE systems were 
initiated via photoinitiation and require an external energy source, commonly ultraviolet 
light. Although photoinitiation is a quick and extremely efficient process to generate 
crosslinked networks, thermal initiation at physiological temperatures increases the 
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translation of HIPEs as off-the-shelf bone grafts. Cook and colleagues have pursued the 
thiol-ene polymerization of a tetrafunctional thiol and divinyl ether via thermal initiation 
investigating the effects of initiator type on gelation time and cure kinetics illustrating 
the ability to generate thiol-ene polymerization via thermal initiation.179 Furthermore, 
Sergent et al. have fabricated thiol-ene polyHIPEs crosslinked with a thermal initiator.112 
Although this additional work illustrates the ability to thermal cure thiol-ene materials, 
the cure temperatures exceed 37°C, eliminating the utility in an injectable system. 
Additionally, the utilization of a toxic diluent in these other systems limits their use as an 
injectable graft option. Currently, thermal polymerization to produce thiol-ene 
chemistries has not been pursued as a means to decrease hydrolytic degradation rate in 
an injectable polyHIPE system. 
To this end, we further developed our injectable polyHIPE system to exhibit a 
tunable hydrolytic degradation rate based on the concentration of a tetrafunctional thiol, 
pentaerythritol tetrakis(3-mercaptoproprionate (tetrathiol). Mass loss under accelerated 
conditions was determined as a means to measure the hydrolytic degradation rate. 
Cytocompatibility of the degradation products was assessed after accelerated 
degradation in water at 80ºC via an adapted extraction dilution viability assay based on 
ISO 10993-5. The effect of a range of tetrathiol concentrations on crosslinking efficiency 
was investigated to probe the contributions of the thiol as a chain transfer agent on 
network properties. Specifically, we monitored rheological properties and determined 
the work and set time in response to thiol incorporation as well as the resulting 
compressive properties. With this work, we have illustrated the utility of β-thioesters as a 
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moiety to increase the degradation rate in polyHIPEs and decrease the need for large 
amounts of initiator potentially increasing the viability of encapsulated cells. This work 
further exhibits the exciting potential of PFDMA polyHIPEs as quick-curing injectable 
bone grafts. 
3.2 Materials and Methods 
3.2.1 Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Palsgaard. All other 
chemicals were purchased and used as received from Sigma–Aldrich, unless otherwise 
noted. Human mesenchymal stem cells were provided by the Texas A&M Health 
Science Center College of Medicine Institute for Regenerative Medicine at Scott & 
White. 
3.2.2 PFDMA Synthesis and Purification 
Propylene fumarate dimethacrylate (PFDMA) was synthesized in a two-step 
process adapted from Timmer et al.149 Briefly, propylene oxide was added dropwise to a 
solution of fumaric acid and pyridine in 2-butanone (2.3:1.0:0.033 mol) and refluxed at 
80°C for 16-18 hours. Residual propylene oxide and 2-butanone were removed by 
distillation, residual acidic byproducts and water were removed with washing, and the 
product was dried under vacuum. The diester bis(1,2 hydroxypropyl) fumarate product 
was then end-capped with methacrylate groups in an addition process with triethylamine 
(TEA) and methacryloyl chloride (MAC). The molar ratios of the diester, MAC, TEA 
were 1:2.1:2.1, respectively. Hydroquinone was added at a molar ratio of 0.008:1 to 
diester to inhibit crosslinking during the synthesis. The reaction was maintained below   
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-10˚C to reduce undesirable side reactions and stirred vigorously overnight under a 
nitrogen blanket. The product was washed overnight in 2 M potassium carbonate to 
neutralize methacryloyl chloride after which the PFDMA was passed through a 
chromatography column loaded with alumina at a 9:1 molar ratio alumina:TEA to 
remove any residual TEA and methacrylic acid. The product was then washed in 
deionized water to remove any alumina and subjected to a brine wash and stirred over 
anhydrous sodium sulfate to remove water. The PFDMA product was dried under 
vacuum and the structure confirmed using H NMR (300 MHz, CdCl3) δ 1.33 (dd, 3H, 
CH3), 1.92 (s, 3H, CH3), 4.20 (m, 2H, -CH2-), 5.30 (m, 1H, -CH-), 5.58 (s, 1H, -
C=CH2), 6.10 (s, 1H, -C=CH2), 6.84 (m, 2H, -CH=CH-). The integration ratio of 
methacrylate protons to fumarate protons in the 1H NMR spectra was used to confirm > 
90% functionalization for all macromers prior to polyHIPE fabrication. 
3.2.3 PolyHIPE Fabrication 
HIPEs were prepared using a FlackTek Speedmixer DAC 150 FVZ-K according 
to a protocol adapted from Moglia et al.180 Redox initiation was utilized to create a quick 
curing HIPE that resembles the work and set time of current PMMA bone cement. 
Molecular structures of PFDMA and pentaerythritol tetrakis(3-mercaptoproprionate) 
(tetrathiol) are shown in Figure 3.1. Two equal amounts of PFDMA were first mixed 
with 1 wt% of organic phase soluble initiators BPO or TMA in a speedmixer cup. Next 
10 wt% surfactant, polyglycerol polyricenoleate (PGPR 4125), was added before 
emulsification. Tetrathiol was added at either 5 or 10 molar percent to the organic phase. 
Tetrathiol amounts were chosen as the maximum amount that could be incorporated  
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Figure 3.1. Molecular structure of A) propylene fumarate dimethacrylate (PFDMA) and 
B) pentaerythritol tetrakis(3-mercaptoproprionate) (tetrathiol) 
 
 
without drastically reducing the resulting polyHIPE compressive properties. Once 
thoroughly mixed, the aqueous solution of calcium chloride (1 wt%) and deionized water 
was then added to the organic phase (75% v) in six additions and mixed at 500 rpm for 
2.5 min each to promote emulsion formation. The two HIPEs (BPO and TMA) were 
mixed at 2500 rpm for 30 seconds in the Speedmixer to initiate crosslinking. HIPEs were 
transferred to either 2 mL microcentrifuge tubes or 15 mL centrifuge tubes and placed in 
a 37°C aluminum bead bath to facilitate crosslinking overnight.  
3.2.4 Determining Pore Architecture 
Scanning electron microscopy (SEM, Phenom Pro, Nanoscience Instruments) 
was utilized to qualitatively determine polyHIPE pore architecture. PolyHIPE sections 
were subjected to vacuum drying for 48 hours to remove water prior to imaging. Circular 
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specimens from three separate polyHIPE specimens were sectioned into quarters, 
fractured at the center, coated with gold, and imaged.  
3.2.5 Work and Set Time 
Work and set times of the polyHIPEs were characterized using an Anton Paar 
MCR 301 rheometer following a procedure adapted from Foudazi et al.181 HIPEs were 
injected onto the plate heated to 37ºC through a mixing head to facilitate redox initiation. 
Storage and loss moduli were measured every 15 seconds using a parallel-plate 
configuration with a 1 mm gap and 0.5% strain. Work time is presented as the onset of 
increasing storage modulus and set time is presented as the tan δ minimum, which 
corresponds to storage modulus yielding. The data represents samples (n=3) from three 
different HIPEs for each composition.   
3.2.6 Compressive Testing  
The effect of thiol concentration on polyHIPE compressive modulus and strength 
was investigated following ASTM D1621-04a. PolyHIPEs cured in 15 mL centrifuge 
tubes were sectioned into disks with a 3:1 diameter to height ratio using an Isomet saw 
(Buehler) and compressed using an Instron 3300 at a strain rate of 50 mm/s. The 
compressive modulus was calculated from the slope of the linear region and the 
compressive strength was identified, after correcting to zero strain, as the stress at the 
yield point or 10% strain, whichever point occurred first. Reported moduli and strength 
data were averages of the disks for each polyHIPE composition (n=9). 
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3.2.7 Accelerated Degradation In Vitro 
PolyHIPEs cured in a 15 mL centrifuge tube were sectioned using an Isomet saw 
(Buehler) into 1 mm thick sections. Specimens were vacuum dried for 48 hours after 
which dry weights were recorded. Accelerated degradation was carried out at a ratio of 1 
g specimen to 20 mL in 0.25 and 0.5 M NaOH for four weeks. Samples were secured 
with Teflon weights in the solution and placed on a shaker table at 37°C. The solutions 
were changed every 2-3 days with time points every week for four weeks. At each time 
point, n=3 specimens were washed twice with RO water, incubated for 1 hr with 1 mL 
RO water to remove any salts, and dried for 48 hours before weighing.   
3.2.8 Gel Fraction 
PolyHIPEs cured in a 15 mL centrifuge tube were sectioned 1 mm thick using an 
Isomet saw (Buehler) vacuum dried for 48 hours. Weighed specimens were suspended in 
dichloromethane (DCM) at a ratio of 1 mL DCM to 10 mg of sample to facilitate 
dissolution of uncrosslinked macromer. Sections in DCM were placed on a shaker table 
at room temperature for 48 hours. After incubation period, DCM was removed and 
specimens were vacuum dried for 48 hours. The gel fraction was determined as the 
fraction of mass loss over original dry mass (n=6). PGPR was accounted for in all 
calculations so that the gel fraction reflected all macromer that was crosslinked into the 
network.  
3.2.9 Statistical Analysis  
The data are displayed as mean ± standard deviation for each composition. A 
Student’s t-test was performed to determine any statistically significant differences 
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 between compositions. All tests were carried out at a 95% confidence interval (P<0.05). 
3.3 Results and Discussion 
The focus of this work was to fabricate quick-curing, injectable polyHIPE bone 
grafts with degradation rates that can be tuned to match new tissue growth. The reaction 
of a thiol with the vinyl of an acrylate or methacrylate has been shown to enhance the 
hydrolytic degradation rate due to an increase in atomic charge of the ester carbonyl 
from the electron pull of the sulfide. Thiol polyHIPEs fabricated in the past utilized toxic 
solvents and were cured with UV radiation. Here we expand on our injectable PFDMA 
polyHIPE system to fabricate highly interconnected monoliths with tunable degradation. 
Given that successful HIPE fabrication is dependent on characteristics such as 
monomer/macromer hydrophobicity and viscosity, it was important to first assess HIPE 
formation and emulsion stability. The tetrathiol has a logP of 1.0 and a viscosity of 0.41 
Pa.s compared to PFDMA with a logP of 3.4 and 0.13 Pa.s viscosity. Despite these 
differences in molecular hydrophobicity, all compositions formed stable HIPEs and 
cured to rigid, interconnected monoliths, as illustrated in Figure 3.2. Likely, the low 
concentration of tetrathiol in the organic phase and rapid cure of the PFDMA HIPE 
limited any effects on polyHIPE architecture. This understanding is beneficial for future 
work in fabricating HIPEs with tunable degradation rates for range of physiological 
degradation rates. 
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It is well established that thiols behave as chain transfer agents during the 
polymerization of vinyls.171, 172, 182-184 Thiols are often utilized as chain transfer agents in 
acrylic polymerizations to control the molecular weight and polydispersity of the  
 
Figure 3.2. Scanning electron micrographs of PFDMA/tetrathiol polyHIPEs A) PFDMA 
control B) 5 mol% tetrathiol C) 10 mol% tetrathiol 
 
 
 
 
Figure 3.3. Effect of tetrathiol acting as a chain transfer agent on PFDMA network 
formation A) No tetrathiol B) 5 mol% tetrathiol C) 10 mol% tetrathiol 
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 products.182, 183 During the propagation step of the PFDMA polymerization, two 
reactions can occur at the methacrylic radical: addition of another PFDMA chain or 
hydrogen abstraction/chain transfer of the radical to the thiol.171 A schematic of network 
formation with increasing molar ratio of tetrathiol is shown in Figure 3.3.The effect of 
this reaction on resulting polyHIPE properties was then characterized.  
3.3.1 Effect of Tetrathiol on Work and Set Time  
Work time, as defined in Chapter II, is essentially the time at which a physician 
can manipulate and inject the graft without altering any material properties. The set time 
is the point at which the material has reached its gelation point and the network is set. 
These two properties were determined utilizing rheology as a method to generate 
reproducible, quantitative data. PFDMA polyHIPE work and set time decreased with the 
addition of tetrathiol as seen in Figure 3.4. The ~1.5 minute work time of PFDMA was 
reduced to 15 seconds with the addition of either 5 or 10 mol% tetrathiol. Similar trends 
were observed with the set time of these polyHIPEs. No significant difference in work 
and set times was observed between thiol concentrations utilizing this method. The 
addition of the thiol radical coupled with the traditional chain growth propagation of 
radical polymerization is hypothesized to result in increased reaction rates and decreased 
work and set times. Furthermore, the thiol-methacrylate reaction is not inhibited by 
oxygen, resulting in the maintenance of quick cure times in aerobic environments.170 
Quick-curing HIPE formulations can be advantageous as well to reduce the time in 
which phase separation can occur before the emulsion geometry is set, thereby ensuring 
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more homogenous pore architectures.113 According to ISO 5833, acrylic based cements 
should have a set time of 10-15 minutes. Although the presented set times are 
approximately 10X faster than these standard values, the cure times can be readily 
increased by decreasing redox initiator concentration, initiator ratios, and chemistries as 
has been shown previously in PFDMA polyHIPEs.180 Currently ferrocene is being 
scouted as a reducing agent to potentially increase cytocompatibility and reduce the 
amount of initiator required to maintain quick cure times.  
 
 
  
 
Figure 3.4. Effect of tetrathiol concentration on rheological properties A) Work and set 
time decrease with the addition of tetrathiol B) Representative plot of storage modulus 
illustrates the increase of work time (onset of storage modulus) and set time (yielding of 
storage modulus) with tetrathiol 
 
 
3.3.2 Effect of Tetrathiol Concentration on PolyHIPE Compressive Properties 
PFDMA/tetrathiol polyHIPE compressive modulus and strength were assessed to 
ensure the incorporation of thiol did not drastically reduce mechanical integrity. A 
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decrease in compressive modulus and strength was observed with an increase in 
tetrathiol concentration as seen in Figure 3.5. PFDMA polyHIPEs fabricated with 
greater than 10 mol% tetrathiol were much weaker and had properties similar to soft 
tissue and were not further characterized. PFDMA polyHIPEs with 10 mol% tetrathiol 
resulted in an average compressive modulus of 15 MPa and strength of 0.7 MPa. While 
this is lower than the average values for human trabecular bone, in vivo studies in animal 
models illustrated bone healing with materials exhibiting compressive properties on the 
low end of trabecular bone.53, 156 The hypothesized mechanism for this trend is the result 
of the thiol as a chain transfer agent. When the thiol abstracts the radical this reduces 
chain propagation and length thereby decreasing crosslink density and results in a 
decrease in compressive properties. A similar decrease in compressive modulus with 
increasing amount of trithiol was observed by Rydholm et al. in poly(ethylene glycol)-
based hydrogels.169 Recent work is focused on incorporating additional methacrylate-
functionalized monomers into the HIPE organic phase to further modulate viscosity for 
cell encapsulation. PolyHIPEs fabricated from these monomers alone have increased 
crosslink density and therefore increased compressive properties. As a result, it is 
probable that modulating the molar ratio of PFDMA:methacyrylated-monomer will 
result in an increase in compressive properties relative to standard PFDMA polyHIPEs. 
3.3.3 Effect of Tetrathiol on Gel Fraction 
Gel fraction was used to assess crosslinking efficiency to further determine the 
effect of the tetrathiol on network formation. Overall gel fraction increased with the 
increase in tetrathiol concentration as displayed in Figure 3.6. The data displayed is after  
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accounting for the loss of PGPR during swelling in DCM which does not attribute to the 
crosslinked network. The gel fraction values were as follows: PFDMA control 
polyHIPEs exhibited 85%, 5 mol% tetrathiol showed 87%, and 10 mol% tetrathiol 
 
Figure 3.5. Effect of tetrathiol concentration on PFDMA polyHIPE compressive 
modulus and strength 
 
 
 
 
Figure 3.6. Effect of tetrathiol concentration on crosslinking efficiency of PFDMA 
polyHIPEs 
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 resulted in 92%. As was seen with the effect of work and set times, the addition of the 
thiol radical increased number of reactive sites within the network and most likely 
attributed to the increase in gel fraction. In the PFDMA control polyHIPEs, it is 
hypothesized that reduced radical diffusion and steric hindrances due to PFDMA and 
tetrathiol organic phase viscosity resulted in reduced crosslinking efficiency and 
remaining unreacted macromer. The increase in crosslinking efficiency with the addition 
of the tetrathiol can be attributed to the reaction kinetics that are uninhibited by oxygen, 
and the thiol acting as a chain transfer agent. These mechanisms decrease the 
propagation of long chains thereby reducing any problems the effect  of steric hindrance 
has on hindering reactive radical ends from finding unreacted methacrylates. Similar 
studies with lower molecular weight monomers illustrated gel fractions near 100%.180 
Therefore, reducing PFDMA/tetrathiol organic phase viscosity with these methacrylated-
monomers is hypothesized to further increase gel fraction of resulting monoliths.    
3.3.4 Degradation Rate 
The overall goal of fabricating thiol-methacrylate polyHIPEs was to generate 
scaffolds with a tunable degradation profile for future matching with in vivo neotissue 
formation. The use of β-thioesters to decrease the electronegativity of the carbonyl of the 
ester and thereby increase the hydrolytic degradation rate has been explored.163 
Schoenmaker et al. demonstrated an increase in atomic charge on the carbon atom of the 
carbonyl of an ester the closer the sulfur atom was positioned to the ester. The electron 
pull from the sulfur increases the positive charge on the carbonyl rendering it more 
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susceptible to hydrolytic attack. Accelerated degradation scouting studies were 
conducted at a range of sodium hydroxide concentrations to determine what conditions 
would be effective in illustrating the effect of tetrathiol on PFDMA polyHIPE 
degradation. The 0.25 and 0.5 M NaOH solutions were utilized to differentiate the effect 
of increasing tetrathiol incorporation on hydrolytic degradation. Values reported reflect 
mass loss after accounting for the theoretical mass of the surfactant, PGPR. To this end, 
an increase in mass loss was observed with an increase in tetrathiol concentration when 
assessed in basic, accelerated conditions as seen in Figure 3.7. All PFDMA/tetrathiol 
polyHIPEs exhibited complete loss of integrity by 3 weeks whereas the PFDMA control 
 
 
 
Figure 3.7. PFDMA/tetrathiol polyHIPE degradation in accelerated conditions at 37°C 
A) 0.25 M NaOH and B) 0.5 M NaOH 
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loss of integrity by 3 weeks whereas the PFDMA control polyHIPE maintained ~35% 
mass loss after the initial mass loss at 1 week. Initial PFDMA mass loss at one week can 
be attributed to the removal of unreacted macromer which can be further supported with 
the lower gel fraction of PFDMA control polyHIPEs. PFDMA polyHIPEs exhibit a gel 
fraction of 85% and FTIR analysis of DCM solutions post swelling illustrates residual 
methacrylated-macromer. Another explanation is the formation of microgels, which are 
intramolecularly crosslinked macromolecules with low molecular weights, which would 
degrade at a much faster rate than the fully crosslinked network.185 The two week 
specimens for the 10 mol% thiol polyHIPEs in the 0.5 M NaOH condition did not 
behave similarly to the three and four week specimens under the same conditions. These 
specimens used for later time points had lost integrity by two weeks. Therefore, two 
week data for the 10 mol% thiol polyHIPEs is most likely an outlier. Overall, this work 
illustrates the ability to alter the organic phase chemistry to increase hydrolytic 
degradation rate without drastically affecting pore architecture or compressive 
properties. 
Previously, polyHIPEs fabricated using multi-arm acrylates and trithiols 
exhibited ~15-35% mass loss in 0.1 M NaOH, 37°C accelerated conditions comparable 
to the results observed in the 0.1 M NaOH initial scoutings.113 Although an increase in 
degradation rate was observed in vitro, the in vivo degradation rate of these specific 
polyHIPE formulations is unknown and would need to be explored in an animal model. 
However, multiple studies illustrate evidence of in vivo degradation of poly(propylene 
fumarate) injectable cements with a similar chemical structure as PFDMA in rat models 
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at 5-6 weeks thus indicating promise for the tunable in vivo degradation of 
PFDMA/tetrathiol polyHIPEs from months to a year.186, 187  
3.4 Conclusions 
Tissue engineered scaffolds are designed to degrade at a rate comparable to 
neotissue growth to provide space for cells to proliferate and lay down new extracellular 
matrix and reduce any long-term complications from material remaining in the body. In 
this work, PFDMA polyHIPEs were fabricated with a tetrathiol to increase hydrolytic 
susceptibility of the ester and finely tune the hydrolytic degradation rate for future use in 
bone grafting applications. Resulting network formation efficiency, cure properties, 
compressive modulus and strength, and in vitro degradation rate were assessed. The role 
of the thiol as a chain transfer agent in the radical polymerization of PFDMA resulted in 
decreased work and set times, increased crosslinking efficiencies, and decreased 
compressive properties. Accelerated degradation studies demonstrated a complete loss of 
integrity of PFDMA/tetrathiol polyHIPEs at 3 weeks with the PFDMA control 
stabilizing at 40% mass loss over 4 weeks. The rate of healing in bone differs widely due 
to physiology of the defect, health of the patient, and severity of injury. Therefore, 
understanding how to modulate polyHIPE chemistries and pore architecture to dictate in 
vivo healing rate is advantageous in addressing large bone defects. Current studies are 
underway to investigate the effect of reducing organic-phase viscosity with small 
monomers and the resulting effect on network formation, compressive properties, and 
degradation rate. The results from this work provide additional tools for use in 
modulating polyHIPE rheological and compressive properties while increasing the rate 
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of degradation for improved design of injectable bone grafts to address healing rates in a 
range of defect physiologies and with patients of various ages and health conditions. 
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CHAPTER IV 
EVALUATION OF  HUMAN MESENCHYMAL STEM CELL BEHAVIOR AND 
BONE INTEGRATION*  
4.1 Introduction 
Tissue engineers focus on harnessing the body’s innate ability to regenerate and 
heal. One key facet of the tissue engineering paradigm is the fabrication of a 3D scaffold 
that not only provides the mechanical support and degradation profile to match neotissue 
formation but also provides a cell niche to stimulate adhesion, proliferation, and 
extracellular matrix production. The template polymerization of high internal phase 
emulsions produces highly porous and interconnected monoliths with tunable properties, 
as discussed in Chapters II and III, for use in injectable bone grafting applications. 
However, further tuning and design must be done to ensure these injectable polyHIPEs 
are cytocompatible and promote desired cellular processes. 
Injectable systems that have the viscosity to mix with a cell suspension and 
integrate with native tissue to provide site-targeted cell delivery have gained interest in 
the biomaterials field. Specifically, aqueous-phase soluble materials such as hydrogels 
are advantageous due to the ease of incorporating cells and bioactive agents without 
killing or denaturing any components. Although hydrogels can be functionalized with 
cell-responsive peptides or fabricated with natural polymers to achieve superior 
___________________________ 
* Reprinted with permission from “Achieving Interconnected Pore Architecture in Injectable PolyHIPEs 
for Bone Tissue Engineering,” by Jennifer L. Robinson, Robert S. Moglia, Melissa C. Stuebben,  et al, 
Tissue Engineering Part A 2014, 20 (5-6), 1103-1112. Copyright (2014) Mary Ann Liebert, Inc. 
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bioactivity, the compressive properties are limited to soft tissue applications. Therefore, 
a rigid polyHIPE graft that promotes hMSC viability and proliferation while providing 
appropriate mechanical properties is desired.  
The use of polyHIPE monoliths to support cell viability and proliferation has 
been pursued by multiple groups. Akay and colleagues initially illustrated the potential 
of styrene-divinylbenzene based emulsion-templated monoliths to support osteoblast 
growth and proliferation.47 Post-fabrication processing techniques including coating 
procedures and covalent functionalization have been used to attach bioactive 
components onto these porous polyHIPE scaffolds. Traditional styrene-divinylbenzene 
polyHIPEs have been coated with laminin and poly-D-lysine, functionalized with 
galactose, and grafted with a range of proteins for enhanced bioactivity.94, 115, 130, 188 
Furthermore, efforts have focused on fabricating polyHIPEs with natural polymers to 
confer bioactivity for enhanced cellular interactions. Barbetta et al. translated HIPE 
fabrication technology to oil-in-water emulsions with dextran, pullulan, and gelatin with 
excellent interconnected pore morphology and support of mouse retinal neural cells.114 
Bokhari and colleagues illustrated the ability of styrene-divinylbenzene-hydroxyapatite 
polyHIPEs fabricated with a hydrogel containing a self-assembling peptide to enhance 
osteoblast ingrowth and support osteogenesis.104 The work by Viswanathan et al. utilized 
the intrinsic phase separation properties of amphiphilic block copolymers within a 
styrene-divinylbenzene polyHIPE system to modulate surface hydrophobicity and 
thereby control protein adsorption on the surface, further tuning cellular adhesion and 
interactions.189 PolyHIPE technology has been further commercialized as a system for 
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3D cell culture sold as Alvetex®, illustrating the ability of these scaffolds to support cell 
viability and proliferation in a 3D environment.105 Although this work resulted in 
scaffolds which enhanced 3D cell proliferation and performance, all of these polyHIPEs 
were fabricated with solvent and cured at temperatures greater than physiological 
temperature, limiting the ability to encapsulate and maintain viable stem cells prior to 
curing for injection into the defect site.  
 Cytocompatibility of all polyHIPE components in an injectable system is crucial 
as post-fabrication techniques to remove cytotoxic components are impossible. For 
materials that are prefabricated and cured ex vivo, the scaffold is typically washed and 
any cytotoxic components are extracted prior to implantation; however, for materials 
that cure in vivo, additional testing and characterization must be conducted to ensure all 
components, any heat generated, and/or  products created during the hardening process 
are cytocompatible. Additionally, the increased production of radicals during the 
initiation and propagation steps of the polymerization reaction must be considered in 
regard to cell viability. Bryant et al. investigated the cytocompatibility of commonly 
used photoinitiators and the concentrations at which these small molecules could be used 
without eliciting a cytotoxic effects.190 This work illustrated good cell viability at low 
initiator concentrations (< 0.01 w/w%); however, common thermally cured systems 
require initiator concentrations ~100X greater when cured at physiological temperatures 
due to the high decomposition temperature of the initiator. Finally, the cytocompatibility 
of uncured macromer is an important parameter to assess. This requires ensuring that all 
reactants, solvents, and side products created during the synthesis of the macromer have 
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been removed prior to HIPE formation. These numerous additional cytocompatibility 
concerns in an injectable system highlight the importance of in vitro characterization and 
scaffold development to promote cell adhesion and viability.  
This work details the development of a cytocompatible, injectable polyHIPE 
which retains the pore architecture, cure times, compressive properties, and degradation 
rates detailed in earlier chapters. Viability of hMSCs in contact with initiators, the 
surfactant PGPR, and PFDMA, BDMA, and tetrathiol macromers was determined using 
both direct and indirect cell culturing methods. The effect of culture conditions including 
overnight serum concentration and hMSC seeding density on resulting cell morphology 
was evaluated. Subsequently, the ability of the polyHIPEs to inject into irregular defects 
and integrate with bone was investigated.  A porcine femur model was utilized to 
determine the integration and retention of the injected polyHIPE in a defect site. 
Furthermore, the ability to maintain hMSC viability post-encapsulation in 
PFDMA/BDMA HIPE was assessed. The studies presented and discussed encompass the 
iterative process in ensuring that the injectable polyHIPE graft is cytocompatible 
throughout injection, cure, and remodeling.  
4.2 Materials and Methods 
4.2.1 Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Palsgaard (Morris 
Plains, NJ).  Human mesenchymal stem cells were provided by the Texas A&M Health 
Science Center College of Medicine Institute for Regenerative Medicine at Scott & 
White. KRGDS peptide was purchased from CelTek Biosciences. All other chemicals 
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were purchased and used as received from Sigma Aldrich (Milwaukee, WI) unless 
otherwise noted.  
4.2.2 BDMA Inhibitor Removal  
Butanediol dimethacrylate (BDMA) was passed through a column containing 
alumina oxide using high air pressure to remove the monomethyl ether hydroquinone 
inhibitor and collected in a round bottom flask.  
4.2.3 PolyHIPE Fabrication  
HIPEs were prepared using the FlackTek Speedmixer DAC 150 FVZ-K. Briefly, 
PFDMA was mixed with 10 wt% surfactant (PGPR) in the Speedmixer cup prior to 
emulsification. For bone integration studies, 5 wt% BPO was added to the organic phase 
to initiate radical crosslinking. In later studies evaluating hMSC viability and behavior 
on quick-curing polyHIPEs, two separate HIPEs were made each with either the 
oxidizing redox initiator (BPO) or reducing initiator (TMA or Ferrocene) added to the 
organic phase. Tetrathiol was added to the organic phase at 5 and 10 mol% to investigate 
the effect of macromer on hMSC cytocompatibility. Once thoroughly mixed, the 
aqueous solution of calcium chloride (1 wt%) and deionized water was then added to the 
organic phase (75% v) in six additions and mixed at 500 rpm for 2.5 min each to 
promote emulsion formation. For redox-initiated polyHIPEs, the two HIPEs (BPO and 
TMA) were mixed at 2500 rpm for 30 seconds in the Speedmixer to initiate crosslinking. 
HIPEs were transferred to either 2 ml microcentrifuge tubes or 15 ml centrifuge tubes 
and placed in a 37°C aluminum bead bath to facilitate crosslinking overnight.  
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4.2.4 Cytocompatibility of Individual HIPE Components 
4.2.4.1 Initiator and Surfactant Cytocompatibility 
The cytocompatibility of individual HIPE components was assessed initially to 
ensure all components were individually cytocompatible. Initiator cytocompatibility was 
evaluated at concentrations that encapsulated cells would experience following a 
protocol adapted from Bryant et al.190 Briefly, the initiators benzoyl peroxide (BPO) and 
4, N,N – trimethylaniline (TMA) were dissolved in a 6 vol% ethanol solution and added 
to media for a final concentration of 0.03 wt% ensuring the amount of solvent in the 
media was 0.6 vol%. Control wells exposed solely to 0.6 vol% of each solvent were 
tested simultaneously to ensure no effect from the solvents on viability. PGPR 
cytocompatibility was assessed at concentrations that reflect what could leach out and 
affect encapsulated cells. PGPR was added to media at 0.1, 1.0, and 5.0 wt% after 
determining that cells would see 0.2 wt% in a 10 wt% PGPR polyHIPE. Bone marrow-
derived human mesenchymal stem cells (hMSCs) were obtained as Passage 1 in a 
cryovial from the Center for the Preparation and Distribution of Adult Stem Cells. Cells 
were cultured in growth media containing 16.5% fetal bovine serum (FBS, Atlanta 
Biologicals), 1% L-glutamine (Life Technologies) and Minimum Essential Media α 
(MEM α, Life Technologies) to 80% confluency and utilized at Passages 5 and 6. Cells 
were seeded directly on tissue culture polystyrene in the media containing initiator or 
surfactant at a density of 2000 cells/cm2. A Live/Dead® assay was utilized to determine 
the viability of hMSCs in contact with dissolved initiators at 3, 24, and 72 hours. Rastor 
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imaging (5 images per specimen) was conducted on four specimens per time point 
(n=20) utilizing a fluorescent microscope (Nikon Eclipse TE2000-S). 
4.2.4.2 Macromer Cytocompatibility 
Further investigation of organic phase (initiator and macromer) cytocompatibility 
was performed prior to seeding cells directly on polyHIPE sections to ensure any 
macromer or radicals that diffuse out are cytocompatible. The in vitro cytocompatibility 
of PFDMA and PFDMA with redox initiators (0.5 wt% BPO/ 2.5 wt% TMA and 0.5 
wt% BPO/ 2.5 wt% Ferrocene) was assessed using a modified ISO 10993-5 extraction 
dilution test. Cells were trypsinized with 0.25% Trypsin-EDTA (Life Technologies) and 
seeded at a density of 40,000 cells/cm2 in a 96 well plate and allowed to adhere for 24 
hours. On the following day, 100 µl of each PFDMA/initiator organic phase was 
incubated in 300 µl growth media supplemented with 1 vol% Penicillin-Streptomycin 
(Life Technologies) in a 48 well plate to mimic the ratio of organic to aqueous phase in 
the HIPE. After 10 minute incubation at 37°C, 5 % CO2, the supernatant above the 
macromers was aspirated and diluted to 10 and 100X solutions. This time frame was 
selected based on the cure rates determined previously for these systems and therefore 
the results are based on the maximum time for extraction of unreacted macromer prior to 
cure. Extracted and diluted media (1, 10, and 100X) was then added to cells and cultured 
for an additional 24 hours. Viability was assessed utilizing the Live/Dead® assay kit 
(Molecular Probes). Analysis was completed using a plate reader (Tecan Infinite 
M200Pro) with excitation/emission wavelengths of 485/528 and 528/620 for the calcein-
AM and ethidium homodimer-1 dyes, respectively. Viability was normalized to cells on 
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tissue culture polystyrene. Further studies with the PFDMA macromer investigated the 
effect of washing with DI water at a 1:100 volume ratio and/or vacuum drying for 24 
hours to further purify the macromer before any cell work. The same procedure was 
followed for all extraction dilution viability assays. 
4.2.5 Indirect Cytocompatibility of PFDMA PolyHIPEs 
To ensure all components were cytocompatible in the HIPE system during cure, a 
indirect Transwell® (Corning) well plate system with polycarbonate membrane inserts 
was utilized to access cytocompatibility of any macromer or radicals that could diffuse 
out while the HIPE was hardening. HIPEs were fabricated as stated above utilizing a 
range of redox initiator combinations: 0.5 wt% BPO/2.5 wt% TMA, 0.5 wt% BPO/2.5 
wt% Ferrocene, or 1 wt% BPO/5 wt% TMA. These compositions were chosen based on 
the range of set times, namely 3, 4, and 8 minutes. Cells were trypsinized with 0.25% 
Trypsin-EDTA (Life Technologies) and seeded at a density of 10,000 cells/cm2 onto the 
polystyrene well plate. HIPEs were injected into the respective inserts and plates put in 
incubator. Viability at 3 hours was assessed utilizing the Live/Dead assay kit (Molecular 
Probes).  Cells were washed with PBS, stained with 2 µM Calcein and 2 µM ethidium 
homodimer-1 for 30 minutes in 37°C. Intensity of stains was completed using a plate 
reader (Tecan Infinite M200Pro) with excitation/emission wavelengths of 485/528 and 
528/620 for the calcein-AM and ethidium homodimer-1 dyes, respectively. Following 
this assessment, the same Transwell® system was utilized to ensure any leachables from 
the cured polyHIPE monolith were cytocompatible. PFDMA HIPEs were fabricated with 
either 5 wt% AIBN or 5 wt% BPO as stated previously, subjected to sterilization and 
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wetting ladder, and loaded into inserts. hMSC seeding and analysis was performed as 
stated previously in this section. 
4.2.6 Direct Cytocompatibility of PolyHIPEs 
4.2.6.1 Effect of Serum Concentration and Seeding Density on Morphology 
The effect of in vitro hMSC culture techniques on PFDMA polyHIPEs was 
assessed to establish effective protocols for determining cell response to the monoliths. 
hMSCs stained with CellTracker™ Orange were utilized in initial studies to visibly 
assess morphology, adhesion, and spreading. PFDMA polyHIPEs fabricated with 5 wt% 
AIBN were utilized for two studies looking at the effect of overnight FBS concentration 
and seeding density on cell behavior. One day prior to seeding, cells were stained with 
10µM CellTracker™ Orange (Molecular Probes) for 45 minutes in 37°C, 5% CO2 and 
replenished with growth media overnight. Specimens were sectioned and sterilized as 
stated previously and subjected to a wetting ladder and progressive solvent extraction 
with PBS. Wafers were incubated overnight with growth media supplemented with FBS 
to increase the amount of protein adsorption to provide increased integrin binding sites. 
To investigate the effect of overnight FBS concentration on cell adhesion and 
morphology, polyHIPE sections were soaked overnight in 10, 40, or 70 wt% FBS in 
αMEM. CellTracker™ Orange stained cells were seeded at 2,000 cells/scaffold and 
imaged at 6 hours.  After determining 40 wt% resulted in enhanced adhesion and more 
spread cells, this concentration was utilized for the remaining studies. To determine the 
effect of seeding density on 72 hour cell adhesion and morphology, stained hMSCs were 
seeded at 2,000, 10,000, and 250,000 cells/ml ( ~ 60, 300, and 2000 cells/ml of 
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polyHIPE). Once it was determined that the higher seeding density resulted in a spread 
monolayer of cells on the polyHIPEs at 72 hours, cells were seeded at a density of 
250,000 cells/ml (~7000 cells/ml of polyHIPE) for all other studies in this section. 
hMSC behavior was observed using a fluorescent microscope (Nikon Eclipse TE2000-
S).  
4.2.6.2 Effect of Initiator on Morphology after Direct Seeding 
Initial cell work was conducted on PFDMA polyHIPEs initiated with AIBN. 
However, once the laboratory started fabricated quick-curing redox polyHIPEs with 
BPO, the majority of the remaining cell work was conducted with BPO/TMA initiated 
polyHIPEs. Evaluation of OCT-stained hMSC morphology on polyHIPEs crosslinked 
with either 5 wt% BPO or 5 wt% AIBN was completed to compare any effect from the 
two initiators. After observing a decrease in cell spreading on BPO-initiated polyHIPEs, 
additional studies focused on decreasing the BPO concentration while maintaining quick 
set times and compressive properties. Therefore, 24 and 72 hour viability was assessed 
on PFDMA and BDMA polyHIPEs initiated with 1 wt% redox (0.5 wt% BPO and 0.5 
wt% TMA) following protocols detailed earlier.  
4.2.6.3 Effect of Increased Gel Fraction on Cell Viability 
Cell viability after 1 week was assessed on polyHIPEs made with 70:30 and 
50:50 molar ratios of PFDMA:BDMA. These HIPE compositions have the reduced 
viscosity necessary to promote mixing with cell suspension that is the subject of 
encapsulation studies in Chapter V. It was also hypothesized that this composition had a 
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higher gel fraction than PFDMA polyHIPEs with a corollary improvement in 
cytocompatibility. 
4.2.7 Cytocompatibility of PFDMA/Tetrathiol PolyHIPEs 
A β-thioester was incorporated into PFDMA polyHIPEs to increase the 
electronegativity of the carbonyl for increased hydrolytic degradation rate. Investigation 
of hMSC viability and morphology was done to assess any effect of the tetrathiol on cell 
behavior compared to control PFDMA polyHIPEs. A macromer extraction dilution 
viability assay was conducted on PFDMA supplemented with 5 and 10 mol% tetrathiol 
and tetrathiol as a control. The extraction was done for 10 minutes and 10 and 100X 
dilutions were made. Viability was assessed as discussed previously. Following indirect 
viability analysis, hMSCs were seeded directly on PFDMA/tetrathiol specimens. 
PolyHIPEs were fabricated utilizing 0 or 10 mol% tetrathiol, cured in 2 ml 
microcentrifuge tubes, and sectioned into 500 µm thick wafers using the Isomet® saw. 
Specimens were sterilized for 3 hours in 70% ethanol, washed 4 times with PBS, and 
incubated overnight in basal media supplemented with 40 w/v% FBS at 5% CO2, 37°C. 
Cells were utilized at Passages 4-6 and trypsinized with 0.25% Trypsin-EDTA (Life 
Technologies) and seeded at a density of 10,000 cells/cm2 onto the polyHIPE sections.  
Viability at 24, 72 hours and 1 week was assessed utilizing the Live/Dead assay kit 
(Molecular Probes). Cells were washed with PBS, stained with 2 µM Calcein and 2 µM 
ethidium homodimer-1 for 30 minutes in 37°C, and replaced with PBS for imaging. 
Rastor imaging (5 images per specimen) was conducted on four specimens (n=20) 
utilizing a fluorescent microscope (Nikon Eclipse TE2000-S). After determining that 
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PFDMA/tetrathiol polyHIPEs exhibited poor gel fraction and resulting viability, gel 
fraction was increased by reducing the organic phase viscosity with BDMA. HIPEs were 
fabricated with PFDMA and BDMA at a 1:1 molar ratio and 10 mol% tetrathiol and 
utilized as discussed previously to determine hMSC viability. A Transwell™ extraction 
study was conducted on the 1:1 PFDMA:BDMA control and 10 mol% tetrathiol 
polyHIPE sections.  
4.2.8 Gel Fraction 
Gel fraction of polyHIPEs fabricated with low and high viscosity macromers and 
a range of initiator concentrations was done to determine any correlation with hMSC 
viability. PolyHIPEs cured in a 15 mL centrifuge tube were sectioned 1 mm thick using 
an Isomet saw (Buehler) vacuum dried for 48 hours. Weighed specimens were 
suspended in dichloromethane (DCM) at a ratio of 1 mL DCM to 10 mg of sample to 
facilitate dissolution of uncrosslinked macromer. Sections in DCM were placed on a RT 
shaker table for 48 hours. After incubation period, DCM was removed and specimens 
were vacuum dried for 48 hours. The gel fraction was determined as the fraction of mass 
loss over original dry mass. PGPR was accounted for in all calculations so that the gel 
fraction reflected all macromere that was crosslinked into the network. 
4.2.9 Synthesis of Cell Adhesive Amphiphile 
An amphiphile containing the integrin-binding sequence RGDS was rationally 
designed utilizing logP values to self-assemble at the pore wall thereby providing 
binding sites for hMSCs. RGDS is an amino acid sequence located in the extracellular 
matrix glycoprotein fibronectin which has been shown to promote cell interaction when 
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incorporated into synthetic polymer matrices.84 Octadecyl isocyanate (OI), the largest 
fatty acid, was reacted with the primary amines on the lysine-terminated RGDS at a 2:1 
molar ratio. Briefly, KRGDS was dissolved in dimethylsulfoxide (DMSO) and loaded 
into a syringe with a needle. Octadecyl isocyanate added to reaction vial was mixed and 
KRGDS added dropwise to the OI. Reaction proceeded for 24 hours at 40°C under 
anhydrous conditions. After reaction was completed, excess solvent was removed using 
high vacuum. Successful functionalization was determined using fourier transform 
infrared (FTIR) spectroscopy.  
4.2.10 Rheology – Work and Cure Time for Encapsulation 
The effect of initiator concentrations in media HIPEs on work and set time was 
determined for future encapsulation studies. Work and set times of the polyHIPEs were 
characterized using an Anton Paar MCR 301 rheometer following a procedure adapted 
from Foudazi et al.181 HIPEs were injected onto the plate heated to 37ºC through a 
mixing head to facilitate redox initiation. Storage and loss moduli were measured every 
15 seconds using a parallel-plate configuration with a 1 mm gap and 0.5% strain. Work 
time is presented as the onset of increasing storage modulus and set time is presented as 
the tan δ minimum, which corresponds to storage modulus yielding. The data represents 
three runs (n=3) from one HIPE of the encapsulation composition. 
4.2.11 Compressive Testing for Encapsulation PolyHIPEs 
The compressive modulus and strength of media PolyHIPEs crosslinked with 
lower ratios of the redox initiators BPO and Ferrocene were determined following 
ASTM D1621-04a. PolyHIPEs cured in 15 mL centrifuge tubes were sectioned into 
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disks with a 3:1 diameter to height ratio using an Isomet saw (Buehler) and compressed 
using an Instron 3300 at a strain rate of 50 mm/s. The compressive modulus was 
calculated from the slope of the linear region and the compressive strength was 
identified, after correcting to zero strain, as the stress at the yield point or 10% strain, 
whichever point occurred first. Reported moduli and strength data were averages of the 
disks (n=3). 
4.2.12 Cell Behavior Post Encapsulation in Rigid HIPE 
The ability to encapsulate and deliver viable hMSCs in a rigid foam to the defect 
site would address current limitations with hydrogel delivery systems which are 
mechanically weak. HIPEs were fabricated following the protocol in Chapter III using 
basal media (αMEM) as the aqueous phase. BDMA was mixed with 10 wt% PGPR and 
0.25 wt% BPO/0.5 wt% Ferrocene. Once the HIPE was fabricated, it was loaded into the 
large side of a 10:1 double barrel syringe using a syringe and 16G needle. hMSCs at 
Passage 5 were trypsinized, counted, and loaded into the small side of the double barrel 
syringe. Cells were encapsulated at 0.3 million cells/mL HIPE. Mixing of the HIPE with 
cell suspension was achieved by injecting through a mixing head. HIPEs were cured in 
between microscope slides with a 500 µm gap held by spacers, transferred to a 48 well 
plate, and covered with 300 µl growth media. Viability was determined at 3 Live/Dead® 
viability assay. Cells were washed with PBS, stained with 2 µM Calcein and 2 µM 
ethidium homodimer-1 for 30 minutes in 37°C, and replaced with PBS for imaging. The 
effect of encapsulated cells on polyHIPE pore architecture was assessed using SEM on a 
respective control and experiment specimens (n=1). 
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4.2.13 PolyHIPE Injection and Integration with Bone 
The space-filling ability of a 10 wt% PGPR HIPE was evaluated utilizing an ex 
vivo porcine femur model. Cylindrical voids 1 cm in diameter and 0.5 cm in depth were 
created with a Dremel rotary tool in the femur and injected with the HIPE. After curing 
in the bead bath, the bone with polyHIPE was sectioned utilizing a low speed Isomet® 
saw and imaged utilizing a scanning electron microscope (SEM) (JEOL 6500). The 
ability for injectable PFDMA polyHIPEs to fill the defect site without overflow or loss 
of material was evaluated utilizing an inverted porcine femur model. Three cylindrical 
voids with a diameter of 1 cm and depth of 0.5 cm were created with a Dremel rotary 
tool, injected with HIPE solution, and the bone with HIPE inverted in a 37°C water bath 
overnight. After overnight cure, each defect in the bone was cross-sectioned into three 
specimens utilizing a low speed Isomet® saw and imaged utilizing a scanning electron 
microscope (JEOL 6500, n=9). All bones utilized in these studies were donated by the 
Rosenthal Meat Science and Technology Center at Texas A&M University. The flow 
properties are important for an injectable bone graft to ensure the material will integrate 
with the defect and remain at the site prior to cure. The feasibility of utilizing PFDMA 
polyHIPE to evaluate the in vivo integration and healing was assessed in a non-load 
bearing rat cranial defect. A critical-size defect with a diameter of 8 mm was created in 
the rat cranium using a dental bur with an outer diameter of 6.9 mm. PFDMA HIPEs 
were fabricated and loaded in a double-barrel syringe with mixing head as discussed 
previously and injected into the cranial defect. Digital photographs were taken to 
document the procedure. 
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4.2.14 Statistical Analysis 
The data are displayed as mean ± standard deviation for each composition. A 
two-tailed Student’s t-test was performed to determine any statistically significant 
differences in all sets of data. All tests were carried out at a 95% (p < 0.05) except the 
gel fraction studies with PFDMA and BDMA which were done at a 99% confidence 
interval (P<0.01). 
4.3 Results and Discussion 
 The work in this chapter details the progression of evaluating polyHIPE 
cytocompatibility. Initial work on macromers, surfactant and initiators was conducted 
separately before incorporating into the HIPE to ensure all components were 
cytocompatible prior to cure. Afterward, indirect viability assays on cured monoliths in 
which cells were not directly seeding on the polyHIPE sections were done to determine 
cytocompatibility of any leachables. Finally, the viability of cells directly seeded on 
polyHIPE sections determined any effects surface chemistry and hydrophobicity had on 
protein adsorption and cell adhesion. All of these studies were vital in developing a 
HIPE system which promotes hMSC viability and proliferation during and post cure for 
future encapsulation work. 
4.3.1 Cytocompatibility of Individual HIPE Components 
4.3.1.1 Initiator and Surfactant Cytocompatibility 
Determining the cytocompatibility of new macromers, initiators, and other 
components is a critical step in designing and implementing novel biomaterials. To this 
end, the viability of hMSCs seeded with media containing either organic-phase soluble 
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BPO and TMA initiators or the surfactant PGPR was evaluated. Each component was 
dissolved in the media following a protocol adapted from Bryant et al.190 Figure 4.1 
illustrates the resulting viability of hMSCs in media with varying concentrations of 
dissolved PGPR. In the HIPE systems with 10 wt% PGPR, the maximum concentration 
cells would experience was calculated at 0.2 wt% in the media. PGPR, which is 
commonly used in the fabrication of chocolate, was cytocompatible at all concentrations 
investigated providing evidence that any future cytotoxic effect was not due to the 
surfactant. 
 
 
 
Figure 4.1. Viability of hMSCs in direct contact with PGPR at 3, 24, and 72 hours 
 
 
Similar studies were run to investigate the cytocompatibility of BPO and TMA. 
However, no cells were adhered at 3 hours indicating these initiators at the 
concentrations tested affected hMSC adhesion. Furthermore, the media with a phenol red 
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pH indicator turned yellow when BPO was added indicating acidic pH. These results 
warranted future studies in initiator cytocompatibility under conditions mimicking the 
HIPE system with all components.  
4.3.1.2 Macromer Cytocompatibility 
An extraction dilution viability assay altered from ISO 10995-3 was done to determine 
the cytocompatibility of the organic phase without PGPR, which was shown to be 
cytocompatible. The initial extraction dilution was conducted on the organic phase with 
PFDMA and initiators (either 0.5 wt% BPO/2.5 wt% Ferrocene or 0.5 wt% BPO/2.5 
wt% TMA) to investigate cytocompatibility of diffusible macromere during cure. All 
extractions in growth media were done for at a 1:3 volume ratio macromer: media to 
mimic the ratio of organic to aqueous phase in the HIPE. Extractions were done for 10 
minutes as this is the maximum estimated cure time any for all potential redox HIPE 
compositions. This experiment indicated that the macromer alone was causing cell death 
(< 5% viability compared to polystyrene controls) as shown in Figure 4.2. PFDMA 
macromer was then purified further by washing at a 1:100 volume ratio with deionized 
water and/or subjecting to high vacuum for 24 hours followed by an additional 
extraction dilution viability assay. Figure 4.2 illustrates an increase in hMSC viability 
when PFDMA is washed and placed under vacuum to remove any residual acid, base, or 
solvents not detectable using analytical techniques (NMR, FTIR). Future work will 
determine protocols to extensively purify PFDMA in large batches for in vitro and in 
vivo studies. Extensive studies in the Mikos group have illustrated in vitro 
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cytocompatibility and in vivo biocompatibility of poly(propylene fumarate) biomaterial 
systems.61, 68, 146 
 
 
Figure 4.2. 10 minute extractions and dilutions based on ISO 10993-5 A) Percent 
viability on PFDMA macromer extractions with 0.5 wt% BPO/ 2.5 wt% ferrocene, 0.5 
wt% BPO/ 2.5 wt% trimethylaniline, or no initiator B) Percent viability on PFDMA 
macromer extractions after further purification procedures 
 
 
4.3.2 Indirect Cytocompatibility of PolyHIPEs 
 After testing and altering components and purification protocols to ensure all 
HIPE components were cytocompatible, indirect culture methods were utilized to 
decouple the effects of hMSC adhesion from the effect of possible diffusion of 
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macromer and radicals from uncured HIPE and leachables from polyHIPE sections. 
First, a Transwell® culture system with polycarbonate membrane inserts was employed 
to determine any cytotoxicity during cure. hMSCs were seeded on the polystyrene wells 
and uncrosslinked PFDMA HIPEs with varying ratios of BPO/TMA or BPO/Ferrocene 
were injected into the inserts and covered with growth media. Cell viability after 
exposure to any diffused macromer or radicals from the HIPE compositions was 
assessed using the Live/Dead stains as seen in Figure 4.3.  These indirect contact studies 
of hMSCs with injectable polyHIPEs with different initiators and ratios resulted in 
spread cells and good viability (~80-85%) comparable to empty Transwell® inserts at 3 
hours.  These results indicated cytocompatibility of any diffusible components that 
encapsulated cells could experience during cure. Additionally, cytocompatibility of any  
 
 
 
Figure 4.3. Transwell® study investigating the cytocompatibility of any diffusible 
macromer and radicals during cure of polyHIPEs with either BPO/Ferrocene or 
BPO/TMA initiator systems 
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polyHIPE leachables was done using the same Transwell® culture system with 
polycarbonate membrane inserts. PFDMA polyHIPEs fabricated with either 5 wt% 
AIBN or BPO were placed in inserts after subjecting to sterilization and a wetting 
ladder. Viability through 72 hours illustrated good cytocompatibility of any leachables 
from the polyHIPE sections, Figure 4.4. This work allowed for future studies 
investigating cell behavior (adhesion, spreading, and morphology) when seeded directly 
on monoliths. 
 
 
 
 
Figure 4.4. Transwell® study investigating the cytocompatibility of any leachables from 
cured PFDMA polyHIPE monoliths 
 
 
4.3.3 Direct Cytocompatibility of PolyHIPEs 
4.3.3.1 Effect of Serum Concentration and Seeding Density on Morphology 
Culturing and assessing cell behavior on 3D scaffolds is more difficult than 2D 
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substrates (e.g. tissue culture polystyrene) because this is a new avenue of cell culture 
research. To this end, multiple culturing parameters must be determined for each new 3D 
culture system. The effect of hSMC seeding density and overnight serum incubation 
concentration on qualitative cell adhesion and morphology were determined. FBS 
concentration on hMSC adhesion and morphology was determined after 6 hours of cure. 
Cells were seeded on polyHIPE sections that had incubated in 10, 40, or 70 wt% FBS 
overnight as seen in Figure 4.5. hMSCs seeded onto monoliths with 40 wt% serum 
exhibited the largest relative amount of adhesion and spreading. From this study, 40 wt% 
FBS was chosen as the concentration to continue with in all future work. Figure 4.6 
displays hMSC morphology in response to a range of seeding densities from 2,000 – 
250,000 cells/scaffold. As the number of cells seeded onto the polyHIPEs increased, the  
 
 
 
Figure 4.5. Qualitative effect of overnight fetal bovine serum concentration on hMSC 
adhesion and morphology at 6 hours A) 10 wt% FBS B) 40 wt% FBS C) 70 wt% FBS 
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increase in cell spreading and overall cell number increased. Kim et al. elucidated the 
effect of seeding density on hMSC viability, proliferation, alkaline phosphatase activity, 
and amount of mineralization and saw the highest seeding density group resulted in 
enhanced ALP activity and calcium deposition.191 Thus, the seeding density is important 
in future studies in which hMSC ALP activity and calcium deposition is measured in 
response to bioactive agents.  
 
 
 
Figure 4.6. Effect of initial hMSC seeding density on cell morphology after 72 hours of 
culture A) 2,000 cells/scaffold B) 10,000 cells/scaffold C) 250,000 cells/scaffold. Cells 
were stained with Cell Tracker Orange™ 
 
 
4.3.3.2 Effect of Initiator on Morphology after Direct Seeding 
Early work conducted with hMSC culture on PFDMA polyHIPEs was done with 5 
wt% AIBN. Recent work in the lab progressed to utilizing redox initiation systems to 
produce quick-curing HIPEs with enhanced compressive properties at 24 hours. In these 
compositions, BPO was utilized as the oxidizing agent. The cell morphologies of 
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polyHIPEs fabricated with either AIBN or BPO are illustrated in Figure 4.7. hMSCs 
seeded on AIBN polyHIPEs exhibit  increased spreading and interaction with proteins 
 
 
Figure 4.7. Effect of organic phase initiator on hMSC morphology at 3 hrs on PFDMA 
polyHIPEs. Cells were seeded at 25,000 cells/scaffold. A) 5 wt% BPO B) 5 wt % AIBN 
 
 
on the scaffold compared to that on BPO polyHIPE sections which resulted in balled up 
cells. This observation can be further explained by the lack of cell adhesion on tissue 
culture polystyrene when BPO was dissolved and added to the media for direct analysis. 
Cell-cell signaling studies in 2D by Nelson et al. demonstrated the importance of cell 
spreading and the resulting cell-cell communication on proliferation highlighting the 
importance of cell morphology on polyHIPE sections.192 Although AIBN-initiated 
polyHIPEs elicit better hMSC interactions, AIBN is a poor oxidizing agent limiting its 
use in producing quick-curing monoliths. Therefore, additional studies in this chapter 
probe the ability to decrease initiator concentration while maintaining quick work and 
set times, comparable compressive properties, and interconnected pore architecture. 
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4.3.3.3 Effect of Increased Gel Fraction on Cell Viability 
Viability of hMSCs directly seeded onto redox-initiated polyHIPEs was first 
assessed with PFDMA and BDMA with 1 wt% BPO and TMA. Figure 4.8 illustrates a 
decrease in viability at 72 hours of hMSCs on PFDMA to 47% compared to 87% on 
BDMA polyHIPEs with the same amount of surfactant and initiator.  
 
 
 
Figure 4.8. hMSC viability after 3, 24, and 72 hrs directly seeded on PFDMA and 
BDMA 1% redox polyHIPE sections. A) Micrographs illustrating live (green) and dead 
(red) cells on the respective polyHIPE sections at 72 hrs B) Viability of cells at each 
timepoint (n=20) 
 
 
Earlier Transwell™ extraction and extraction dilution viability studies showed that the 
initiator radicals were cytocompatible during cure. Therefore, the effect of uncrosslinked 
macromer was investigated. Initial work on the redox-initiated PFDMA polyHIPE 
system indicated a decrease in crosslinking efficiency compared to BDMA polyHIPEs 
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crosslinked with the same initiator concentration.180 It was hypothesized that this was 
due to the increased viscosity of the PFDMA organic phase relative to BDMA because 
of larger molecular weight. Increased viscosity can reduce radical diffusion and increase 
steric hindrance thereby decreasing crosslinking efficiency leaving unreacted macromer 
in the polyHIPE. Therefore, the effect of any unreacted macromer was determined by 
decreasing HIPE organic phase viscosity with BDMA at molar ratios of 70:30 and 50:50 
and determining the gel fraction and hMSC viability. Figure 4.9 displays the increase in 
crosslinking efficiency with an increase in BDMA due to an overall decrease in organic 
 
 
 
Figure 4.9. Effect of BDMA concentration on crosslinking efficiency assessed by gel 
fraction 
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phase viscosity. All BDMA polyHIPEs exhibited gel fractions significantly higher than 
that of the PFDMA control polyHIPE. Thus, decreasing organic phase viscosity is a 
method to increase crosslinking efficiency in 1 wt% redox polyHIPEs. Solvent 
extraction solutions from the gel fraction procedure contained unreacted macromer as 
shown by fourier transform infrared analysis (data not shown). The effect of the increase 
in crosslinking efficiency and potential decrease in unreacted macromer on hMSC 
viability was assessed. As hypothesized, increasing gel fraction increased hMSC 
viability as seen in Figure 4.10. The effect of unreacted unsaturated bonds may be a 
cause of decreasing viability. Klouda et al. illustrated a decrease in fibroblast viability 
with increased concentration of unreacted acrylated and methacrylated macromers and 
the time in which cells were exposed to these solutions before the network was 
formed.193 This worked established the time of exposure in which cells are tolerable to 
reactive acrylates and methacrylates in this particular system. In the future, a similar 
systematic study should be done to determine what concentrations of macromers and 
initiators and durations of exposure are tolerable by hMSCs. This information will be 
vital in maintaining viability of encapsulated cells in the polyHIPE. 
4.3.4 Cytocompatibility of PFDMA/Tetrathiol PolyHIPEs  
A tetrathiol macromer was incorporated into PFDMA polyHIPEs to tune the 
hydrolytic degradation rate for future modulation to match a range of in vivo bone 
healing rates. The effect of tetrathiol on hMSC viability was first assessed in an 
extraction dilution viability assay.  All concentrations of tetrathiol tested resulted in 
viable hMSCs shown in Figure 4.11. These results supported investigating one week 
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viability of hMSCs directly seeded on PFDMA/tetrathiol polyHIPE specimens. 
However, poor viability was observed on both the PFDMA control and 10 mol% 
tetrathiol PFDMA polyHIPEs after 72 hours of culture, Figure 4.12. However, 
specimens with 10% thiol promoted good cell adhesion and spreading and cells  
 
 
 
Figure 4.10. Effect of BDMA concentration and increased gel fraction on 72 hour 
hMSC viability 
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Figure 4.11. Effect of tetrathiol concentration on hMSC viability using a modified 
extraction dilution live/dead assay based on ISO 10993-5 
 
 
remained at 1 week (42% viability) whereas a negligible amount of cells were adhered 
on PFDMA control specimens after 1 week. Brink et al. observed an increase in cell 
number and cell aggregate area in oligo(poly(ethylene glycol) fumarate) hydrogels with 
poly(ethylene glycol) dithiol compared to control OPF gels indicating a possible effect 
of thiol chemistry on cell adhesion and behavior.194 As discussed previously, it was 
hypothesized that the viscosity of the PFDMA/thiol HIPE inhibited initiator and  
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Figure 4.12. hMSC viability after direct seeding on PFDMA polyHIPEs with 10 mol% 
tetrathiol. No cells were remaining on PFDMA controls at 1 week. 
 
 
macromer diffusion potentially resulting in pockets of uncured macromer and unreacted 
radicals. In response, lower viscosity HIPEs fabricated with a 50:50: molar ratio of 
PFDMA:BDMA were seeded with hMSCs to ascertain the effect of uncured macromer 
on cell adhesion and viability. Gel fraction results in Figure 4.13 display an increase in 
percent of crosslinked material in the polyHIPE as the viscosity decreased giving 
evidence that in PFDMA/tetrathiol HIPEs the poor viability can be attributed to 
unreacted macromer. Thereby, the viscosity of PFDMA/tetrathiol HIPEs was decreased 
by incorporating BDMA at a 1:1 molar ratio. The resulting 1 week viability is shown in 
Figure 4.14. As hypothesized, increasing gel fraction by decreasing organic phase 
viscosity was seen in specimens without tetrathiol. Viability of both tetrathiol 
compositions (with and without BDMA) was comparable at each timepoint. The only 
differences between the PFDMA/BDMA and PFDMA/BDMA/tetrathiol polyHIPEs is 
 106 
 
 
 
 
Figure 4.13. Effect of BDMA on gel fraction with and without 10 mol% tetrathiol 
 
 
the incorporation of the thiol. A Transwell™ extraction study was conducted on 50:50 
PFDMA:BDMA with and without 10 mol% thiol specimens to differentiate the effect of 
extractables compared to direct seeding on polyHIPEs. All values at 24 and 72 hours 
were greater than 80% and comparable between the control and thiol specimens 
indicating a negligible effect of the tetrathiol polyHIPE leachables on cell viability,  
 107 
 
 
Figure 4.14. Effect of decreasing HIPE viscosity on hMSC viability directly on 
polyHIPEs with 10 mol% tetrathiol 
 
 
 
Figure 4.15. Therefore, it is hypothesized that the change in chemistry with the addition 
of the thiol is altering cell behavior at the polyHIPE surface. The tetrathiol is more 
hydrophobic than PFDMA and BDMA (LogP values, increasing value indicates increase 
in hydrophobicity, Tetrathiol =1.0, BDMA = 3.0, PFDMA = 3.4). This microscopic 
increase in polyHIPE surface hydrophilicity may affect the amount and/or conformation 
of adsorbed proteins thereby altering integrin binding sites for hMSCs. Another theory is 
the addition of the thiol-methacrylate reaction and increase in rates of reaction may 
result in an increase in unreacted imitator or radicals. Although viability increased with 
the increase in polyHIPE gel fraction in control specimens, all polyHIPE systems with 
tetrathiol exhibit poor viability a mechanism which is currently being investigated. 
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Figure 4.15. Transwell™ viability assay on 50:50 PFDMA:BDMA polyHIPEs with 10 
mol% tetrathiol at 24 and 72 hours 
 
 
4.3.5 Synthesis of Cell Adhesive Amphiphile 
To increase hMSC adhesion and viability on PFDMA-based polyHIPEs, an amphiphile 
containing RGDS as an integrin binding site was synthesized. The chemistry was 
designed such that the macromolecule would self-assemble at the HIPE pore wall and 
anchor into the organic phase with the RGDS sequence available for cells seeded on top 
or encapsulated in the aqueous phase to recognize. Octadecyl isocyanate was reacted 
with the primary amines on a lysine-terminated RGDS at 40°C, anhydrous, for 24 hours. 
The removal of the isocyanate peak at 2270 cm-1 and the introduction of the carbonyl of 
the urea at 1618 cm-1 indicated successful coupling of the fatty acid chain to the 
adhesion peptide.  FTIR results illustrated these molecular changes are displayed in 
Figure 4.16. Furthermore, a schematic of the reaction and the theoretical location of the 
amphiphile once incorporated are in Figure 4.17. The overall goal of incorporating this  
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Figure 4.16 FTIR spectra illustrating the coupling of octadecyl isocyanate with lysine-
terminated RGDS 
 
 
amphiphile into the HIPE prior to cure is to increase cell adhesion and interaction with 
the polyHIPE without a post-fabrication processing to ensure injectability. An increase 
in spreading was observed of hMSCs seeded on polyHIPE sections with 3 mM RGDS 
amphiphile relative to the polyHIPE control. This knowledge may be further used to 
increase hMSC behavior once encapsulated.  
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Figure 4.17. Schematic illustrating the reaction of octadecyl isocyanate with a lysine-
terminated RGDS to fabricate an amphiphile that will self-assemble at the HIPE pore 
wall to promote hMSC adhesion and spreading. A) Reaction and location B) 24 hr 
analysis of CellTracker™ Orange-stained hMSCs seeded on either a control polyHIPE 
section or a polyHIPE section with 3 mM RGDS amphiphile 
 
 
4.3.6 Cell Behavior Post Encapsulation in Rigid HIPE 
Delivering viable, autologous hMSCs to the defect site would increase healing 
while reducing any rejection which may be caused from using allogeneic tissue. 
Encapsulating cells in a rigid, highly porous foam could address issues of mechanical 
weakness in typical hydrogel systems and provide a substrate that can withstand the 
physiological loading of bone. Two main parameters are currently being modulated to 
ensure encapsulation and viability maintenance with injectable PFDMA-based 
polyHIPEs: adequate viscosity to mix with cell suspension and quick cure time to reduce 
time for diffusion of unreacted macromer and radicals into the cell-laden aqueous phase. 
Figure 4.18 illustrates the proposed injection set-up and the system used to run the in 
vitro studies. A BDMA HIPE with 0.5 wt% BPO and 2.5 wt% Ferrocene was fabricated 
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with basal media as the aqueous phase and loaded in the larger side of a 10:1 double 
barrel syringe. Cells at Passage 5 were trypsinized and loaded in the smaller side in a 
suspension to ensure a 10:1 ratio. This size double barrel syringe was utilized to ensure 
the HIPE could mix completely with the cell suspension. Decreasing organic phase 
viscosity more may allow the use of a 1:1 double barrel while maintaining successful 
mixing of the two phases. A representative micrograph of 3 hr hMSC viability is shown 
in Figure 4.19 illustrating a majority of viable cells post encapsulation. hMSCs were 
visible throughout all sections illustrating the ability to adequately mix the cell 
suspension with the HIPE for increased distribution within the monolith. 
 
 
 
Figure 4.18. Schematic illustrating the potential to encapsulate hMSCs in the injectable 
HIPE within the surgical suite utilizing a double barrel syringe with mixing head setup 
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Figure 4.19. 3 hr hMSC viability post encapsulation in a BDMA HIPE initiated with 0.5 
wt% BPO/ 2.5 wt% Ferrocene 
 
 
The effect of encapsulated hMSCs on pore architecture is illustrated in Figure 4.20. In 
this study, the presence of cells during the cure process destabilized the emulsion and 
resulted in larger, homogenous pore sizes (20-100 µm) and interconnect sizes (5-10 µm). 
It is hypothesized that this effect could be modulated based on the HIPE composition, 
the number of cells encapsulated, and the media components. This effect could be 
utilized to increase interconnected polyHIPE pore size to increase nutrient and waste 
transport through the monolith. The average compressive modulus of this composition at 
24 hour cure (no cells) was 22 MPa and strength of 1.5 MPa. These values are higher 
than typical hydrogel matrices and are comparable to similar scaffolds shown to be 
suitable for promoting healing validating the use of this composition for hMSC 
encapsulation and delivery.53 
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Figure 4.20. Effect of encapsulated hMSCs on pore architecture A) control BDMA 
polyHIPE B) BDMA polyHIPE with 0.3 million cells/ml HIPE encapsulated 
 
 
 
The work time of this HIPE composition allowed for adequate time to load the 
double barrel syringe and inject multiple specimens for cure in a 48 well plate. The set 
time was also important as it is hypothesized that a short set time is ideal to reduce any 
unreacted macromer or radicals which could leach out into the media. This particular 
system exhibited a set time of 1.5 minutes which is much less than the 10 minute 
incubation period in which good viability was seen after the extraction of macromer and 
initiators.  As discussed previously, the impact of organic phase chemistry, initiator 
concentrations, and cure time must be determined in a systematic extraction viability 
study to ascertain what conditions and durations are tolerable to encapsulated hMSCs. 
With this information, hMSC viability and ALP activity will be assessed post 
encapsulation in the predetermined HIPE composition utilizing the established protocols. 
Overall, performance of this study mimics a surgeon adding a bone marrow 
aspirate/concentrate to the double barrel syringe which has been pre-loaded with the 
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HIPE. This technique also precludes the significant cost and time associated with cell 
expansion while retaining the benefits of autologous cell delivery. The facile double 
barrel syringe method provides the proof of concept that an injectable HIPE can be 
combined with cells in the surgical suite without a costly or complex apparatus and 
illustrates the strong clinical translation potential. 
4.3.7 PolyHIPE Injection and Integration with Bone 
Injectable scaffolds that integrate with native tissue are expected to enhance bone 
healing with minimal inflammation and scarring. To this end, the ability of a PFDMA 
HIPE to integrate with native tissue in a porcine femur defect was evaluated. Figure 
4.21 illustrates the microscale integration of the HIPE in an ex vivo porcine femur defect 
evident as evidenced by the lack of gap between polyHIPE and cortical bone.  
 
 
 
Figure 4.21. Injectable PFDMA HIPEs fill irregularly-shaped defects created in a 
porcine femur and integrate with bone without shrinkage upon cure at 37°C. 
 
 
Furthermore, the ability of the HIPE to resist flow and remain at a defect site throughout 
cure was investigated. It was hypothesized that the viscosity of the HIPE will be 
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advantageous in preventing extravasation and result in maintenance of the scaffold at the 
defect. The viscosity of HIPE prior to cure was 11.0 ± 2.3 Pa·s, comparable to 
mayonnaise. Figure 4.22 illustrates the ability of PFDMA HIPE to resist flow when 
inverted in a clear tube. Additionally, the HIPE remains at the defect site in the porcine 
femur during cure when inverted in an aqueous environment. SEM analysis indicated 
integration of HIPE into the bone with no evident gap after inversion in an aqueous 
environment overnight in all nine specimens evaluated.  
 
 
 
Figure 4.22 The viscosity of a PFDMA HIPE prior to cure results in retention of the 
scaffold at the defect site during cure in an aqueous environment. A) HIPE does not flow 
upon inversion in transparent tube. B) Schematic illustrating the inversion of porcine 
femur with HIPE injected in 1 X 1 X 0.5 cm defects in 37°C water bath. C) Digital and 
scanning electron micrographs showing good integration of HIPE with bone during 
inversion in water. 
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Initial studies illustrated the feasibility of using a quick-curing redox HIPE for 
non-load bearing studies in a rat cranial critical-size defect as seen in Figure 4.23. These 
feasibility studies established a platform protocol for future work to evaluate the in vivo 
HIPE integration with bone and the ability of these polyHIPEs to promote osteogenesis. 
Evaluation of the pullout strength will also be conducted to determine the extent to 
which the HIPE has integrated into the native bone. 
 
 
 
Figure 4.23. Preliminary studies in a rat cranial defect illustrate the feasibility of 
injecting HIPEs into non-load bearing defects to later evaluate integration and healing 
 
 
4.4 Conclusions 
The development of a new biomaterial system requires extensive investigation of 
scaffold components to ensure cytocompatibility. Specifically, injectable systems in 
which cells are encapsulated must be designed and processed so that cytocompatibility is 
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maintained prior, during, and post-cure. To this end, all HIPE components and 
concentrations were extensively analyzed to determine under what conditions 
encapsulated hMSCs could remain viable and primed for osteogenesis. Methods were 
first established to successfully assess effects of HIPE components on hMSC viability 
and polyHIPE microstructure and chemistry on cell morphology and behavior. A 
seeding density of 100,000 cells/cm2 (of well plate) and a 40 wt% FBS overnight soak 
were determined to enhance cell adhesion and spreading. Techniques to purify 
macromer were established for use in future encapsulation work. Current investigation is 
focused on determining the maximum initiator concentrations which are tolerable by 
cells. These protocols are useful for in vitro culture of cells on 3D foams and will help 
advance the development of multiple HIPE compositions as tissue engineered scaffolds.  
Moreover, a double barrel syringe and mixing head setup was utilized to efficiently mix 
cells through the HIPE suspension illustrating the proof of concept that an injectable 
HIPE can be combined with cells in the surgical suite without a costly or complex 
apparatus and illustrates the strong clinical translation potential. Furthermore, these 
studies elucidated key structure-property relationships in emulsion templated scaffolds 
that can be used in future studies to modulate cell-material interactions.  
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CHAPTER V 
MATERIAL-INDUCED OSTEOGENESIS IN POLYHIPES WITH CALCIUM 
PHOSPHATE AND DEMINERALIZED BONE MATRIX 
5.1 Introduction 
 Tissue engineered bone grafts combine the healing potential of autografts with 
the availability of allografts. A major challenge in designing functional bone grafts is 
determining a material composition which promotes ingrowth of surrounding bone and 
proliferation of cells (osteoconduction), the differentiation of progenitor cells down an 
osteoblastic lineage (osteoinduction), and osseointegration with native bone. 
Osteogenesis encompasses all of these processes resulting in full tissue regeneration. 
Various scaffold chemistries and bioactive agents are currently studied to provide a 
matrix that provides cues to stimulate osteoblast differentiation of hMSCs and promote 
integration and healing. 
 The most effective approach in designing a 3D scaffold to stimulate osteogenesis 
is to mimic the extracellular matrix of bone. This encompasses the protein chemistries, 
inorganic mineral composition, topography, morphology, compressive properties, and 
degradation rate. Extensive research has focused on recombinant growth factors, such as 
bone morphogenetic proteins (BMPs), for effective osteoblastic differentiation of 
hMSCs. Unfortunately, these potent factors have resulted in undesired tissue growth and 
fatal inflammation. Utilizing inorganic minerals and matrix proteins for differentiation is 
advantageous over growth factors as the decrease in potency may reduce undesired 
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effects while encouraging natural repair based on in vivo cell signaling as a response to 
the material. 
Calcium phosphates comprise the main mineral component of native bone and 
are commonly utilized in bone tissue engineering to promote osteogenesis. Based on 
Ca/P ratio, crystallinity, and degree of impurities, a range of bioactivities and 
degradation rates are achieved with calcium phosphates.1 Hydroxyapatite (HA) has been 
utilized extensively in biomaterial research and illustrated the potential for calcium 
phosphates to promote osteogenesis in vitro. However, in physiological pH, highly 
crystalline HA exhibits poor solubility and hinders cell responses due to low 
concentrations of calcium and phosphate ions released.195 Amorphous calcium 
phosphate lacks any crystal structure and is resorbed more readily than crystalline 
hydroxyapatite.196 The relative ability of these calcium phosphate minerals to stimulate 
progenitor cell proliferation and differentiation are dependent on physiological 
environment and presentation in the scaffold. 
A unique attribute of the HIPE system is the thermodynamics that can drive 
phase separation depending on hydrophobicities of the internal and continuous phase. 
This results in the ability to introduce small particles that can self-assemble at the pore 
surface due to their size and surface charge. Emulsions stabilized by solid particles 
which adsorb to the oil-water interface rather than a molecular surfactant are termed 
Pickering emulsions.86 Multiple groups have successfully fabricated and characterized 
water-in-oil (w/o) Pickering polyHIPEs utilizing both titania and silica nanoparticles.87-
90, 197 The preferential location of self-assembled particles, including the ACP and HA 
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nanoparticles, at the pore wall in direct contact with encapsulated MSCs is beneficial for 
providing a bioactive component that could be utilized for osteoblast differentiation. 
Furthermore, this methodology promotes the ability to use less of the expensive 
bioactive particles and still achieve the desired cellular response due to the presentation 
of the particles in the polyHIPE pore walls with large surface area.  
Demineralized bone matrix (DBM) is proposed to stimulate bone growth by 
providing an environment in which invading progenitor and inflammatory cells are 
stimulated to release trophic cytokines to recruit cells for repair.119 Furthermore, the 
demineralization process exposes growth factors and other bioactive molecules which 
would otherwise remain inactive in the presence of minerals.119, 198 Additional work by 
Pietrzak et al. explained that inorganic minerals reduced hydration of the organic matrix 
limiting the solubility and thereby bioactivity of growth factors such as BMPs.199  
Multiple studies have illustrated the ability for DBM to promote osteogenesis both in 
vitro and in vivo. Incorporating both calcium phosphate and demineralized bone matrix 
into injectable polyHIPEs may provide a rigid foam capable of promoting material-based 
osteogenesis for encapsulated hMSCs. 
The use of polyHIPE monoliths as scaffolds to repair bone has been pursued by 
multiple groups but not widely studied. Bokhari and colleagues incorporated 
hydroxyapatite into styrene-divinylbenzene polyHIPEs and illustrated the ability to 
increase the production of bone matrix glycoprotein osteopontin and mineral deposition 
relative to control specimens.104 These results are promising for use of this emulsion 
templating technique to fabricate rigid materials that promote enhanced behavior of bone 
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cells. However, all of this work was conducted with monoliths that were fabricated, 
extensively washed to purify, and then tested. The ability of an injectable polyHIPE 
fabricated without toxic solvent and cured at 37°C to promote hMSC adhesion and 
differentiation down an osteogenic lineage would increase the use of these materials in 
bone grafting applications. 
In the earlier chapters of this work, polyHIPE compositional and processing 
parameters were utilized to modulate scaffold pore architecture, compressive properties, 
cure time, degradation rate, and interaction with hMSCs. In this chapter, we build upon 
our injectable polyHIPEs with tunable properties to fabricate monoliths with osteogenic 
potential. Amorphous calcium phosphate and hydroxyapatite nanoparticles, and 
demineralized bone matrix were added to the organic phase prior to fabrication to 
increase osteogenesis and hMSC proliferation. Redox-cured polyHIPEs allowed for 
incorporation of particles with a range of hydrophobicities and surface charge due to the 
quick set times which reduces time for phase separation. The ability to incorporate 
bioactive particles into the HIPE without affecting emulsion stability and resulting pore 
architecture was investigated using SEM. The effect of osteoinduction agent on the 
compressive properties of PFDMA/BDMA polyHIPEs was evaluated. Finally, the ability 
of these agents incorporated in the polyHIPE to promote hMSC differentiation in vitro 
was assessed by measuring alkaline phosphatase activity levels and observing hMSC 
calcium deposition with Alizarin red stain in response to ACP, HA, and DBM. The work 
in this chapter is the culmination of the work to develop an injectable polyHIPE for bone 
graft applications. The results from these studies will be utilized to determine injectable 
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HIPE compositions for future studies evaluating in vivo bone growth in a rabbit ulnar 
defect model. 
5.2 Materials and Methods 
5.2.1 Materials 
Polyglycerol polyricinoleate (PGPR 4125) was donated by Palsgaard (Morris 
Plains, NJ).  Human mesenchymal stem cells were provided by the Texas A&M Health 
Science Center College of Medicine Institute for Regenerative Medicine at Scott & 
White. All other chemicals were purchased and used as received from Sigma Aldrich 
(Milwaukee, WI) unless otherwise noted.  
5.2.2 Demineralizing and Homogenizing Rat Long Bones 
 Euthanized Sprague Dawley rats were obtained from the tissue share program at 
the Laboratory Animal Research and Resources facility at Texas A&M University. The 
demineralization process was adapted from Figueiredo et al.200 Long hind bones were 
extracted from the rats, rid of soft tissue using a scalpel and gauze, and the majority of 
marrow removed with water and compressed air. Bones were soaked in a 1:1 volume 
chloroform: methanol solution at 1g bone to 30 mL solution for 3 hours. After solvent 
treatment, bones were washed once with RO water and placed in a 0.6M HCl solution 
and stirred for 24 hours to decalcify. Residual HCl was then removed by rinsing with 
water, stirring DBM in freezing water, and placed under vacuum at 40°C overnight. 
DBM was then blended into smaller pieces and homogenized into particles using a 
handheld digital homogenizer (IKA T25 digital ULTRA-TURRAX). Scanning electron 
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microscopy was utilized to determine relative particles sizes as seen in Figure 5.1. 
Visual assessment determined particle sizes range from 50 – 200 µm. 
 
 
 
Figure 5.1. Demineralized bone matrix particles after homogenization procedure 
 
 
 
5.2.3 BDMA Inhibitor Removal  
Butanediol dimethacrylate (BDMA) was passed through a column containing 
alumina oxide using high air pressure to remove the monomethyl ether hydroquinone 
inhibitor and collected in a round bottom flask.  
5.2.4 PolyHIPE Fabrication 
 Quick-curing redox polyHIPEs were fabricated using the method detailed in 
earlier chapters. A 70:30 molar ratio of PFDMA:BDMA was utilized to ensure an 
adequate viscosity to mix with a cell suspension for encapsulation. The organic phase 
was further comprised of 10 wt% PGPR, 1 wt% BPO or TMA and either 2 wt% 
amorphous calcium phosphate nanoparticles (ACP), 5 wt% hydroxyapatite 
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nanoparticles, or 15 wt% demineralized bone matrix (DBM). The concentrations reflect 
results from scoutings to determine the maximum concentration of osteoinductive 
components that promoted HIPE formation. The aqueous solution of calcium chloride (1 
wt%) and deionized water was then added to the organic phase (75% v) in six additions 
and mixed at 500 rpm for 2.5 min each to promote emulsion formation. The two HIPEs 
(BPO and TMA) were mixed at 2500 rpm for 30 seconds in the Speedmixer to initiate 
crosslinking. HIPEs were transferred to either 2 mL microcentrifuge tubes or 15 mL 
centrifuge tubes and placed in a 37°C aluminum bead bath to facilitate crosslinking 
overnight. 
5.2.5 Pore Size Characterization 
SEM (Phenom Pro, Nanoscience Instruments) was utilized to image all 
polyHIPEs and determine any effect of the incorporation of osteogenic particles on 
polyHIPE pore sizes. PolyHIPEs were subjected to vacuum drying for 72 hours to 
remove water prior to pore architecture characterization. PolyHIPEs cured in 15 ml 
centrifuge tubes were sectioned into thirds, fractured at the center, coated with gold, and 
imaged in a rastor pattern yielding five images. Pore size measurements were completed 
on the first ten pores that crossed the median of each 4000X magnification micrograph. 
Average pore sizes for each polyHIPE composition are reported (n=150). A statistical 
correction was calculated to account for non-perfect spherical pores, ℎ2 = 𝑅2 − 𝑟2,  
where R is the void diameter’s equatorial value, r is the diameter value measured from 
the micrograph, and h is the distance from the center. The average diameter values were 
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multiplied by this correction factor resulting in a more accurate description of pore 
diameter.95  
5.2.6 Compressive Testing 
The effect of each osteoinductive agent on polyHIPE compressive modulus and 
strength was investigated following ASTM D1621-04a. PolyHIPEs cured in 15 mL 
centrifuge tubes were sectioned into disks with a 3:1 diameter to height ratio using an 
Isomet saw (Buehler) and compressed using an Instron 3300 at a strain rate of 50 mm/s. 
The compressive modulus was calculated from the slope of the linear region and the 
compressive strength was identified, after correcting to zero strain, as the stress at the 
yield point or 10% strain, whichever point occurred first. Reported moduli and strength 
data were averages of the disks for each polyHIPE composition (n=3). 
5.2.7 Alizarin Red Staining of ACP and HA in PolyHIPE 
Alizarin red binds to calcium ions and was utilized to visually verify the 
incorporation of calcium phosphate particles. PolyHIPEs of each condition were 
sectioned to 1 mm width using an Isomet saw (Buehler). Specimens were first fixed with 
3.7 vol% glutaraldehyde followed by a 5 minute incubation in 2 w/v% alizarin red in 
distilled water solution, pH 4.1-4.3. Stained specimens (n = 1) were washed with 
distilled water 5X to remove any unreacted dye. Digital micrographs were obtained. 
5.2.8 Sirius Red Staining of Type I Collagen  
Sirius red, which preferentially binds to Type I collagen, was used to both verify 
the matrix was collagen and illustrate the incorporation of DBM in the polyHIPEs. A 1 
mg/ml solution of Sirius red was added to specimens and incubated at room temperature 
 126 
 
for 30 minutes. Type I rat tail collagen (Sigma) was utilized as a positive control for the 
stain. Following staining, specimens (n = 3) were rinse with deionized water 5X and 
imaged with a digital camera. 
5.2.9 Cytocompatibility of PolyHIPEs with ACP, HA, and DBM 
Initial cytocompatibility verification of polyHIPEs with 2 wt% ACP, 5 wt% HA, 
and 15 wt% DBM was done following the protocol detailed in Chapter III. PolyHIPEs 
were cured in 2 ml microcentrifuge tubes and sectioned into 500 µm thick wafers using 
the Isomet® saw. Specimens were sterilized for 3 hours in 70% ethanol, washed 4 times 
with PBS, and incubated overnight in basal media supplemented with 40 w/v% FBS at 
5% CO2, 37°C. Cells were utilized at Passages 3 and seeded at a density of 10,000 
cells/cm2 onto the polyHIPE sections.  Viability at 1 and 2 weeks was assessed utilizing 
the Live/Dead assay kit (Molecular Probes). Cells were washed with PBS, stained with 2 
µM Calcein and 2 µM ethidium homodimer-1 for 30 minutes in 37°C, and replaced with 
PBS for imaging. Rastor imaging (5 images per specimen) was conducted on four 
specimens (n=20) utilizing a fluorescent microscope (Nikon Eclipse TE2000-S). 
5.2.10 Osteoconductivity of PolyHIPEs 
The ability of PFDMA/tetrathiol polyHIPEs to promote osteogenesis was 
accessed via alkaline phosphatase (ALP) activity and Alizarin red calcium staining. 
PolyHIPEs were sectioned and subjected to a wetting ladder and overnight serum 
incubation as stated previously. hMSCs were seeded at a density of 105 cells/scaffold 
(well). The ability of polyHIPEs to promote osteogenesis was assessed with ALP 
activity of cells seeded on polyHIPEs cultured in growth media. Cells were lysed at 1, 7, 
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and 14 days. Briefly, media was removed from wells and replaced with 300 µL 
phosphate buffered saline (PBS) and samples subjected to a thermal shock procedure in 
which specimens were placed in 37°C incubator followed by an 80°C freezer 3X to lyse 
the cells and release intracellular ALP. Alkaline phosphatase (ALP) activity was 
accessed using a fluorometric assay kit (Abcam, ab83371) in which ALP cleaves the 
phosphate of non-fluorescent 4-methylumbelliferyl phosphate disodium salt (MUP) 
substrate resulting in a fluorescent signal. A Quant-iT™ PicoGreen® dsDNA Assay Kit 
(Molecular Probes) was utilized to quantify dsDNA to report ALP activity per cell. 
Conversion of MUP substrate to a fluorescent signal by ALP was assessed using a plate 
reader (Tecan Infinite M200Pro) with excitation/emission wavelengths of 360/440 nm, 
respectively. Alizarin red staining was conducted on specimens utilized for viability 
analysis. After imaging for viability, cells on sections were fixed with 3.7% 
glutaraldehyde solution for 10 minutes, washed 1X with PBS, and stored in 300 µL 
distilled water. The staining procedure detailed previously was followed and digital 
micrographs obtained to ascertain relative amounts of calcium deposition across 
conditions. 
5.2.11 Statistical Analysis 
The data are displayed as mean ± standard deviation for each composition. A 
Student’s t-test was performed on the compressive and viability data to determine any 
statistically significant differences between compositions. Tests were carried out at a 
99% confidence interval (P<0.01) for all studies. 
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5.3 Results and Discussions 
5.3.1 Fabrication and Characterization of Osteoinductive PolyHIPEs 
The goal of incorporating osteogenic elements into PFDMA-based polyHIPEs was to 
confer an osteoinductive character to the grafts without negative impact on the desirable 
graft properties such as injectability, porosity, and mechanical properties. Incorporating 
components with a range of hydrophobicities and surface charges into HIPEs is often 
difficult as these changes in chemistries can drastically affect emulsion stability and 
resulting properties. Due to these differences in hydrophobicity, it was hypothesized that 
these particles will self-assemble at the pore wall. This is vital in ensuring encapsulated 
hMSCs will interact with the bioactive agents. Surface enrichment also allows for 
reduced concentrations and minimizes the impact on bulk properties. First, the effect of 
ACP and HA nanoparticles and DBM particles on pore architecture was assessed. All 
compositions formed stable monoliths. Initial scoutings utilizing EGDMA were done to 
determine the maxiumum concentration of each osteogenic element which promoted 
HIPE fabrication. Concentrations of 2 wt% ACP, 5 wt% HA, and 15 wt% DBM were 
the maxium that could be incorporated and were the relative amounts utilized for the 
remainder of studies. PolyHIPEs with a 70:30 molar ratio of PFDMA:BDMA were 
fabricated with the osteogenic components and resulting pore size was analyzed. Redox-
cured polyHIPEs allow for incorporation of particles with a range of hydrophobicities 
and surface charge because quick set time reduces time for phase separation. Figure 5.2 
displays the effect of ACP, HA, and DBM on pore architecture. A quailitative 
assessment of polyHIPE pore size illustrated a negligible effect of ACP, HA, and DBM 
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on HIPE stability at concentrations analyzed. Quantitative analysis of pore size is 
displayed in Table 5.1.   
 
 
 
Figure 5.2. Scanning electron micrographs illustrating resulting polyHIPE pore 
architecture after the incorporation and cure of A) No agent B) 2 wt% ACP C) 5 wt% 
HA D) 15 wt% DBM 
 
 
 
Table 5.1 Effect of osteogenic components on pore size and homogeneity 
 
 
 
The ability of the HIPE to fill and cure around the larger DBM particles with minimal 
gaps is demonstrated in Figure 5.3. These results illustrate the utility of this polyHIPE 
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stystem to incorporate a range of bioactive compenents without altering material 
properties. 
 
 
 
 
Figure 5.3. Scanning electron micrographs illustrating the pore architecture with the 
incorporation of DBM particles A) High magnification micrograph B) Low 
magnification micrograph 
 
 
5.3.2 Compressive Properties of PolyHIPEs with ACP, HA, and DBM 
 A potential advantage of using PFDMA/BDMA polyHIPEs for bone grafts is 
their rigid compressive properties. Therefore, it was important to assess the effect of the 
bioactive agents on the graft compressive modulus and strength. Figure 5.4 shows a 
slight decrease in compressive properties with the incorporation of ACP, HA, and DBM 
on polyHIPE. However, there was no significant difference among modulus values. This 
effect is further explained with the negligible change in pore architecture which greatly 
dictates monolith compressive properties. The ability to incorporate a variety of 
bioactive agents without affecting pore architecture and resulting compressive properties 
provides opportunity to design these polyHIPEs for a multitude of tissue engineering 
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applications. Furthermore, it may be possible to modulate cell response in a dose-
dependent manner by incorporating a range of concentrations of proteins and inorganic 
minerals.  
 
 
 
Figure 5.4. The effect of ACP, HA, and DBM on polyHIPE compressive properties 
when incorporated at indicated concentrations. 
 
 
5.3.3 Calcium and Collagen Staining of PolyHIPEs 
 Staining assays were conducted to verify the presence of the particles at the 
surface of the polyHIPEs sections to ensure direct contact with encapsulated hMSCs.   
Alizarin red staining of calcium ions on polyHIPEs with ACP and HA illustrated the 
presence of these particles at the surface by a positive red stain as seen in Figure 5.5. 
PFDMA films with ACP and HA nanoparticles stained with alizarin red resulted in no 
staining as evidenced in Figure 5.6. It was hypothesized that the particles dissolved in 
the macromer lack any driving force to self-assemble at the film surface unlike the HIPE  
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Figure 5.5. Alizarin red staining of calcium ions in polyHIPEs with A) no agent B) 2 
wt% ACP and C) 5 wt% HA 
 
 
 
 
Figure 5.6. Alizarin red staining of PFDMA films A) no HA nanoparticles B) 5 wt% 
HA nanoparticles 
 
 
system where the change in hydrophobicities at the pore wall promote this self-
assembly. Therefore, the negative staining on the films compared to the positive staining 
on the polyHIPEs illustrates the surface enrichment of these particles in the polyHIPEs. 
The self-assembly of these particles at the pore wall indicates the ability to incorporate a 
lower concentration of bioactive particles while maintaining cellular response due to 
increased surface area of particles at the oil/water interface. Elemental analysis using 
energy dispersive x-ray technology (EDS) on HA specimens is currently underway to 
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further indicate the presence of these particles at the polyHIPE surface. Sirius red 
collagen staining was utilized to locate DBM particles within the polyHIPE. Because 
these particles were larger, visual inspection with the naked eye verified their 
incorporation. Positive staining of these particles within the polyHIPE indicated the 
DBM protocol maintained type 1 collagen-rich particles, Figure 5.7. 
 
 
 
 
Figure 5.7. Sirius red staining of A) control polyHIPE B) 15 wt% DBM polyHIPE 
C) type I collagen from rat tail 
 
 
5.3.4 hMSC Viability and ALP Activity on PolyHIPEs 
 Illustrating the ability of these injectable polyHIPEs to promote material-based 
differentiation of hMSCs down an osteoblastic pathway is one of the major goals of this 
research. As discussed in Chapter IV, initially determining the viability and morphology 
of hMSCs on polyHIPE sections is crucial to moving forward with additional cell 
behavior studies. Two week hMSC viability after direct culture on polyHIPEs with ACP, 
HA and DBM are shown in Figure 5.8. All conditions promoted good viability through 
two weeks. An increase in cell viability was seen with all bioactive agents compared to 
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the PFDMA/BDMA control at one week. PolyHIPEs with ACP, HA, and DBM resulted 
in greater than 85% viability. This may be attributed to increased cell-cell signaling with 
the calcium and phosphate ions and an enhanced frequency of integrin-binding sites 
from the collagen in the DBM.  
 
 
 
Figure 5.8. hMSC 1 and 2 week viability on 70:30 PFDMA:BDMA polyHIPEs with 2 
wt% ACP, 5 wt% HA, and 15 wt% DBM 
 
 
ALP activity was determined from hMSCs cultured on polyHIPE specimens cultured in 
growth media. Typically, researchers utilize osteogenic media supplemented with 
dexamethasone, ascorbic acid and β-glycerol phosphate to determine a material’s 
osteoconductivity in in vitro studies. The results from these studies illustrate the 
osteoconductive nature of the material; however, it is difficult to conclude how the 
material would perform without the addition of potent osteoinductive agents. The work 
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presented here shows an elevation in ALP activity with each bioactive component in 
growth media lacking any additional components, Figure 5.9. Alizarin red staining of  
  
Figure 5.9. Effect of osteoinductive component on hMSC ALP activity at 1 week 
 
 
 
 
 
 
Figure 5.10. Calcium deposition of hMSCs on respective polyHIPE sections 
 
 
one week polyHIPE specimens with cells yielded qualitative evidence that hMSCs are 
depositing calcium as seen in Figure 5.10. Comparing ACP and HA specimens before 
and after cell culture may suggest the increases resorption of ACP in media. The HA 
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staining post cell seeding may be convoluted by residual calcium in the crystalline HA 
particles that have not been utilized by the hMSCs.  
Current work in the laboratory of Dr. Mariah Hahn is focused on determining the 
upregulation of RNA for bone specific proteins osteocalcin and osteopontin as additional 
early signs of these polyHIPEs promoting osteogenesis. Furthermore, stable EGDMA 
polyHIPEs with 2 wt% HA and 10 wt% DBM were fabricated illustrating the potential 
to incorporate multiple bioactive agents to further promote cell adhesion, proliferation, 
and differentiation. Future work will focus on the effect of polyHIPEs containing both 
ACP and DBM to elicit whether there is a synergistic or antagonistic effect. These 
results highlight the potential of these polyHIPEs to elucidate an osteoinductive effect in 
vivo. 
5.4 Conclusions 
ACP, HA, and DBM particles were added to PFDMA-based polyHIPEs to confer 
osteoinductive character and enhance bone regeneration. To this end, stable HIPEs with 
each of these bioactive agents were formed with a range of particle concentrations with 
negligible change in pore architecture and compressive properties. Initial hMSC viability 
testing indicated that the osteogenic agents enhanced cytocompatibility to greater than 
85%. Furthermore, ACP, HA, and DBM particles all enhanced one week ALP activity of 
hMSCs directly seeding on specimens indicating the potential of these functionalized 
polyHIPEs as osteoinductive bone grafts. Overall, this work demonstrates the ability to 
incorporate a range of bioactive components (inorganic nanoparticles and protein 
matrices) into these injectable polyHIPEs to increase cellular interactions and direct 
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specific behavior without compromising scaffold architecture and resulting properties. 
These improved porosity, degradability, and bioactivity as compared to current bone 
cements as well as the improved mechanical properties as compared to bioactive bone 
grafts highlights the potential of these polyHIPE grafts as improved bone grafting 
materials. 
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CHAPTER VI 
CONCLUSIONS 
6.1 Summary 
The work presented here details the fabrication of injectable polyHIPE scaffolds 
with tunable properties for use in delivery autologous mesenchymal stem cells to bone 
defects. These highly porous monoliths address current limitations of autologous and 
allogeneic bone grafts to provide a 3D scaffold which promotes osteogenesis and 
osseointegration. 
PFDMA polyHIPE pore size, interconnected porosity, compressive properties, 
injection parameters, and degradation rate were modulated by altering compositional 
variables (e.g. macromer chemistry, surfactant concentration, initiator chemistry) and 
processing parameters (e.g. mixing speed, storage conditions, time of cure). This 
demonstrated ability to readily tune scaffold properties is expected to improve function 
in a wide range of pathologies. In particular, the rate of healing in bone differs widely 
due to physiology of the defect, health of the patient, and severity of injury. Therefore, 
understanding how to modulate polyHIPE chemistries and pore architecture to tune the 
degradation rate for the promotion of healing is advantageous in addressing large bone 
defects. To this end, a tetrathiol was then introduced into the PFDMA polyHIPEs to 
enhance the hydrolytic degradation rate without compromising the desirable graft 
properties.  
Methods were then developed to characterize hMSC adhesion, spreading, 
viability, and proliferation on polyHIPE specimens. These specific protocols are useful 
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for in vitro culture of cells on 3D foams and will help advance the development of 
multiple HIPE compositions as tissue engineered scaffolds.  A double barrel syringe and 
mixing head setup was then utilized to efficiently mix cells into the HIPE during 
injection and prior to cure. This illustrates the proof of concept that an injectable HIPE 
can be used as a cell carrier. Notably, special care was placed on a design that permitted 
isolation of cells and combination with the HIPE in the surgical suite without a costly or 
complex apparatus to ensure clinical translation potential. These studies also elucidated 
key cell-material interactions in emulsion templated scaffolds that can be used in future 
studies to modulate cell behavior.  
  Finally, these injectable polyHIPEs were fabricated with ACP, HA, and DBM 
particles to confer an osteoinductive character to the rigid polyHIPE grafts. The addition 
of these osteoinductive agents enhanced hMSC viability, ALP activity, and calcium 
deposition on the polyHIPEs. This work demonstrates the ability to incorporate a range 
of bioactive components (inorganic nanoparticles and protein matrices) into these 
injectable polyHIPEs to increase cellular interactions and direct specific behavior 
without compromising scaffold architecture and resulting properties.  Furthermore, these 
injectable polyHIPEs which promote osteogenesis address currently limitations of 
calcium-phosphate based bone cements which exhibit limited porosity and a brittle 
compressive behavior. 
Overall, this body of work highlights the potential of interconnected PFDMA-
based polyHIPEs as injectable scaffolds for bone tissue engineering. Beyond this 
specific application, the structure-property relationships elucidated from this work can 
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be utilized to design functional 3D polyHIPE monoliths with enhanced cell-material 
interactions for a variety of tissue engineering applications. 
6.2 Significance of Work 
PolyHIPEs were fabricated without a toxic solvent, exhibited reaction kinetics 
that promoted cure at physiological temperature, and a viscosity that promoted injection 
and flow into a defect site. Injectable polyHIPEs that cure in situ can advance bone 
grafting procedures by 1) space-filling defect to promote tissue integration; 2) providing 
osteogenic cues to stimulate osteoblast differentiation; 3) and deliver hMSCs to 
stimulate bone growth.  
In Chapter II, compositional and processing variables were altered to modulate 
injectable polyHIPE pore architecture. PolyHIPEs have been investigated for over three 
decades for applications in solid-phase synthesis, catalyst support, and filtration. The 
majority of this work has resulted from trial and error-based studies to achieve scaffold 
properties for the desired application. We focused to mechanistically determine the 
effect of compositional variables on polyHIPE architecture and resulting mechanical 
properties for future rationale design of scaffolds for many clinical applications. Current 
scaffold fabrication techniques focus on porosity or injectability. Achieving a highly 
porous and injectable scaffold with compressive strength and modulus able to withstand 
physiological load is a major challenge in orthopedic tissue engineering. Additionally, 
fabrication techniques that result in a scaffold with relatively high compressive 
properties require post-fabrication modifications before implantation. This work resulted 
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in an injectable, highly porous polyHIPE able to withstand physiological load post 
implantation. 
Incorporation of a β-thioester to increase the hydrolytic degradation rate of 
PFDMA polyHIPEs was discussed in Chapter III. Previous biodegradable polyHIPE 
systems have the capacity to degrade over time; however, the rate at which this process 
occurs cannot match the wide range of bone healing rates which is dependent on the 
physiology of the defect, severity of injury, and health of the patient. Therefore, 
developing a polyHIPE system with a tunable degradation rate is crucial to utilizing this 
product for a range of patients and indications. Modulating the susceptibility of the ester 
carbonyl to hydrolysis via the concentration of the tetrathiol is a means to fabricate 
interconnected polyHIPEs with the same tunable pore architecture and a range of 
degradation rates. 
In Chapter IV, hMSC adhesion, spreading, and viability on injectable PFDMA-
based polyHIPEs were demonstrated. This research resulted in established working 
protocols for all future studies of hMSC behavior on polyHIPE foams. Additionally, 
these studies provided the platform for current work to encapsulate and maintain viable 
hMSCs for one week for autologous stem cells delivery in the surgical suite. This work 
not only elucidated the effects of biocompatible compositional components on the 
tunability of the PFDMA polyHIPE system for bone tissue engineering but also provided 
an understanding of these variables for scaffold fabrication in other clinical applications 
including wound dressings and soft tissue repair. Hydrogels have been a model system 
for encapsulating cells and maintaining their viability for delivery to injured tissue.201 
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However, hydrogel systems are not able to withstand the physiological load necessary 
for promoting osteogenesis. Cells encapsulated in a rigid foam which is capable of 
maintaining mechanical integrity during load is advantageous in ensuring robustness of 
the scaffold as well as providing the mechanotransductive cues necessary for 
differentiating hMSCs into osteoblasts. The innovation and advancement to the field lies 
in the ability to encapsulate hMSCs and maintain viability in a scaffold able to withstand 
physiological load for increased osteogenesis and healing of large, bone defects. 
In Chapter V, bioactive components were incorporated into the polyHIPE during 
fabrication to confer an osteoinductive character to the scaffolds. PolyHIPE fabrication 
with reproducible pore architecture is a sensitive process as emulsion stability, which is 
affected by a multitude of factors, dictates pore architecture crucial for mechanical 
properties and cellular response. In this sense, incorporating additional bioactive 
components into the HIPE fabrication process is difficult as most methods alter phase 
hydrophobicities and change HIPE stability. Incorporating calcium phosphate 
nanoparticles which self-assemble at the oil-water interface circumvents many of the 
issues faced when adding bioactive components to the aqueous phase before HIPE 
fabrication. Furthermore, quick-curing polyHIPEs reduce the time for phase separation 
during cure thereby increasing the ability to incorporate a range of bioactive agents.  
Overall, we have developed injectable polyHIPEs with tunable pore 
architectures, compressive properties, injectability parameters, and degradation rates for 
the use in healing large bone defects. Determining key mechanisms that control scaffold 
properties and resulting cell behavior will be instrumental in designing polyHIPEs for 
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use in delivering autologous cells to promote integration and healing in various tissue 
engineering applications. 
6.3 Future Directions and Challenges 
 Detailed in this work is the development of injectable polyHIPE scaffolds with 
tunable properties and osteoinductive potential. Although we have illustrated monolith 
cytocompatibility and the ability to promote osteogenic differentiation in vitro, 
additional work must be done to ensure these grafts promote osteogenesis in vivo.  
 Multiple properties of the polyHIPE scaffold may need to be modulated to better 
promote cellular ingrowth and viability of encapsulated cells. It has been reported that 
pore sizes ranging from 50 – 400 µm are required to promote full bone healing.46 We 
have a great understanding of how to control emulsion stability which dictates pore size. 
However, in this work we report a maximum pore size of ~ 30 µm for PFDMA 
polyHIPEs and indicate that it may be possible to use hydrophilic polymers (PEG) in 
EGDMA (lower viscosity) to drive osmosis and phase separation resulting in larger 
pores. Utilizing the reagents and techniques we have established with the work and 
previous HIPE work in our lab, we can further investigate using organic phase 
combinations with a higher concentration of lower viscosity macromer and longer set 
times to increase the time for phase separation. Preliminary work illustrated a 
homogenous increase in pore size after incorporating hMSCs into the HIPE system. 
Additional studies will determine the reproducibility of this effect and additional effects 
of cell number on emulsion stability. Furthermore, adding higher concentrations of 
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osteoinductive particles could result in decreased emulsion stability which could be 
controlled by the fast cure of redox HIPEs to reduce inhomogeneity of pore sizes.    
 Increasing blood flow into the polyHIPE constructs may be necessary to increase 
oxygen distribution to cells in the bulk of the scaffold. Adequate and timely 
vascularization of tissue engineered scaffolds is important to provide vital metabolites, 
inflammatory cells, and stem cells to signal healing. Researchers have engineered ways 
to pre-vascularize the scaffold prior to implantation by suturing the material to the 
periosteum. The delivery of growth factors such as VEGF and PDGF, which are potent 
inducers of angiogenesis and stable vasculature formation, has also been investigated for 
tissue engineered scaffolds. The co-delivery of BMP-2 and VEGF has been shown to 
enhance healing due to a signaling pathway and feedback loop between the two growth 
factors.202 Our laboratory is currently fabricating and characterizing polyHIPE 
microspheres for the delivery of proteins. BMP-2 and VEGF could be incorporated into 
these delivery vehicles and mixed into the polyHIPE monoliths with the potential to 
increase vascularization in these injectable polyHIPEs. The HIPE system, with adequate 
viscosity to flow and remain around the defect site, is advantageous with the potential to 
cure around microvasculature within the defect providing an alternative method to 
promote angiogenesis within the bulk of the polyHIPE. 
 The native, hierarchical structure of bone results in great compressive strength 
and increased toughness and plasticity. An issue with traditional calcium phosphate bone 
cements is their brittle compressive properties. Therefore, one goal of the injectable 
polyHIPEs is to increase monolith toughness without sacrificing modulus and strength. 
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Initial work done in our lab illustrated the ability to increase polyHIPE toughness with 
the addition of 10 mol% tetrathiol. This effect was observed drastically with EGDMA 
polyHIPEs and less with BDMA and PFDMA networks. Therefore, polyHIPEs 
comprised of ratios of EGDMA and PFDMA with 10 mol% tetrathiol may result in an 
increase in toughness without a significant change in modulus and strength.   
 Further investigation on the preparation of the demineralized bone matrix 
particles may be done to elicit their maximum effect on osteoblastic differentiation. The 
degree of demineralization and particle size of DBM has been shown to alter in vitro and 
in vivo osteogenic differentiation.121 DBM de-calcified to 2% residual calcium and 
particle sizes ranging from 500 – 710 µm resulted in the largest amount of calcium 
deposition and enhanced ALP activity. Thus, this effect should be pursued in the current 
70:30 PFDMA:BDMA polyHIPE system to potentially increase the response of hMSCs. 
The larger particle sizes may also increase HIPE stability and result in larger pore sizes 
which remain homogenous. 
 Furthermore, it is probable that the hMSC-polyHIPE interactions should be 
enhanced to increase viability and proliferation and reduce the need for an excess of 
cells during encapsulation. The incorporation of the integrin-binding sequence, RGDS, 
was discussed in Chapter IV via the self-assembly of a conjugated amphiphile at the 
pore wall. While we illustrate the potential for this design to increase hMSC adhesion 
and spreading, an alternate method may need to be explored. A couple of research 
groups have illustrated the ability to fabricate polyHIPEs using natural polymers in the 
internal phase or functionalizing with peptides post-functionalization. While these 
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methods lacked injectability, the potential to utilize natural polymers within the HIPE 
system should be explored. Furthermore, functionalizing bioactive macromolecules and 
covalently attaching them into the network may provide binding sequences for cells at 
the pore wall. Adding acrylated gelatin into PFDMA polyHIPEs to increase hMSC 
interactions was attempted during the early part of this work without any effect on cell 
adhesion. With the understanding of HIPE properties in quick-curing HIPEs from 
Chapter II and the development of protocols that provide good viability and 
characterization of cell behavior on 3D monoliths in Chapter IV, it is possible that 
incorporating natural polymers now may result in more promising results. Also, Madl et 
al. incorporated a thiol-functionalized BMP2 mimicking peptide into a hydrogel for 
covalent binding into the network to increase osteogenic differentiation.203 A similar 
chemistry functionalized with any bioactive peptide (e.g. RGDS) could be utilized 
within the thiol-ene polyHIPEs to potentially increase cellular interaction. The viability 
of hMSCs encapsulated in injectable polyHIPEs must be maintained for at least one 
week in vitro to illustrate the potential of these polyHIPEs to promote bone healing in 
vivo. To this end, a systematic, throughput study must be conducted to determine which 
organic phase composition (macromer combination, amount of unsaturated bonds after 
set time, and initiator concentration) combined with shorter set times promotes good 
viability of encapsulated hMSCs. Once the candidate composition is determined, hMSC 
viability, proliferation, and ALP activity will be investigated for two weeks. Illustrating 
good cell behavior in vivo will allow for translation of the technology into small animal 
models. Preliminary animal studies will provide information on any polyHIPE properties 
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that must be altered to best promote osseointegration and healing. Osseointegration and 
upregulation of bone markers will be evaluated in both a non-loaded (rat cranial) and a 
loaded (rabbit ulnar) defect model. The in vivo results may indicate the necessity to 
increase pore size, increase vascularization into the polyHIPE, and eventually increase 
matrix toughness. At this point, our understanding of the requisite tools to tune 
polyHIPE properties will be vital in future iterations of the design to address the needs of 
bone healing. 
 While additional work and challenges exist before these injectable polyHIPEs 
can be utilized as a clinical option for bone grafting procedures, a platform technology 
has been established that can readily be tuned and adjusted to address future results of in 
vivo studies. Protocols were established after determination of the driving mechanisms 
that affect pore architecture and resulting compressive properties. The alteration in 
organic phase chemistry to modulate degradation rate or promote osteogenic 
differentiation had a negligible effect on scaffold properties illustrating the ability to 
incorporate a range of chemistries and bioactive peptides to enhance in vivo behavior. 
Overall, these injectable polyHIPEs have the potential as autologous cell delivery 
vehicles which can degrade at a rate comparable to neotissue formation and promote 
osteogenesis upon injection.  
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